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POSTPRANDIAL EFFECTS OF THREE ISOCALORIC HIGH-FAT MEALS WITH DIFFERING LIPID 
LOADS ON TRIGLYERCIDES, OXIDATIVE STRESS, AND ENDOTHELIAL FUNCTION 
 
BACKGROUND: There have been numerous studies that compare the relationship of postprandial 
lipemia, oxidative stress, and endothelial dysfunction, but there is a lack of information as to the dose 
response nature of isocaloric high-fat meals (HFM). OBJECTIVE: To examine the dose response of 
lipemia (isocaloric HFM consisting of ~25%, ~50%, and ~75% fat) on plasma triglycerides (TG), oxidative 
stress, and endothelial function. It was hypothesized that the highest fat load would produce the greatest 
amount of oxidative stress and endothelial dysfunction; whereas each lipid load would be significantly 
higher than the previous. METHODS: Ten young inactive healthy men (22.8 ± 2.9 yrs) participated in 
three randomized challenge meals consisting of 25%, 50%, and 75% fat. Endothelial function, as 
measured by flow-mediated dilation (FMD) and blood samples were taken at baseline, 2 and 4 hours 
postprandial. Samples were assayed for blood biomarkers of TG and oxidative stress (3-nitrotyrosine (3- 
NT) and thiobarbuiuric acid reactive substances (TBARS)). RESULTS: TG were found to be significant 
with the 50% fat meal compared to the 25% fat meal (p = .001); but not between the other comparisons. 
Significance was also found for TG between 25% and 50% fat meals at 2 hours postprandial (p = .000) 
but not for any of the other comparisons. No changes were observed with either measure of oxidative 
stress. FMDs were found to be significant with the 50% fat meals compared to the 25% fat meal (p = 
.026), and the 75% fat meals compared to the 25% fat meal (p = .002); but not between the 50% and 
 
75% fat meals (p = .142). Significance was also found for FMDs at 2 hours postprandial between 25% 
 
and 75% fat meals (p = .027) and at 4 hours postprandial between 25% and 50% (p = .017) and 25% and 
 
75% fat meals (p = .013). CONCLUSIONS: Thus, it appears young healthy inactive men do not exhibit a 
dose response in lipemia following an isocaloric HFM consisting of 25%, 50%, and 75% fat. Interpretation 
of the oxidative stress and endothelial dysfunction results are more difficult to interpret without a dose 
response in lipemia. However, other measures of oxidative stress should be considered before strong 
conclusions can be drawn. 
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Abstract 
 
 
BACKGROUND: There have been numerous studies that compare the relationship of postprandial lipemia, 
oxidative stress, and endothelial dysfunction, but there is a lack of information as to the dose response nature 
of isocaloric high-fat meals (HFM). OBJECTIVE: To examine the dose response of lipemia (isocaloric HFM 
consisting of ~25%, ~50%, and ~75% fat) on plasma triglycerides (TG), oxidative stress, and endothelial 
function. It was hypothesized that the highest fat load would produce the greatest amount of oxidative stress 
and endothelial dysfunction; whereas each lipid load would be significantly higher than the previous. 
METHODS: Ten young inactive healthy men (22.8 ± 2.9 yrs) participated in three randomized challenge meals 
consisting of 25%, 50%, and 75% fat. Endothelial function, as measured by flow-mediated dilation (FMD) and 
blood samples were taken at baseline, 2 and 4 hours postprandial. Samples were assayed for blood 
biomarkers of TG and oxidative stress (3-nitrotyrosine (3-NT) and thiobarbuiuric acid reactive substances 
(TBARS)). RESULTS: TG were found to be significant with the 50% fat meal compared to the 25% fat meal (p 
= .001); but not between the other comparisons. Significance was also found for TG between 25% and 50% fat 
meals at 2 hours postprandial (p = .000) but not for any of the other comparisons. No changes were observed 
with either measure of oxidative stress. FMDs were found to be significant with the 50% fat meals compared to 
the 25% fat meal (p = .026), and the 75% fat meals compared to the 25% fat meal (p = .002); but not between 
the 50% and 75% fat meals (p = .142). Significance was also found for FMDs at 2 hours postprandial between 
25% and 75% fat meals (p = .027) and at 4 hours postprandial between 25% and 50% 
(p = .017) and 25% and 75% fat meals (p = .013). CONCLUSIONS: Thus, it appears young healthy inactive 
men do not exhibit a dose response in lipemia following an isocaloric HFM consisting of 25%, 50%, and 75% 
fat. Interpretation of the oxidative stress and endothelial dysfunction results are more difficult to interpret without 
a dose response in lipemia. However, other measures of oxidative stress should be considered before strong 
conclusions can be drawn. 
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Introduction 
 
 
Atherosclerotic cardiovascular disease (CVD) is  the  leading cause of  morbidity and  mortality in 
western society and will soon become the pre-eminent health problem worldwide [1, 2]. Atherosclerosis 
originates in the inner most cellular lining of the artery, the endothelium. The endothelium is a key regulator of 
vascular homeostasis, due to it not only functioning as a barrier for the vessel but through anti-atherogenic 
functions [3].   The endothelium acts to maintain the balance between vasodilation and vasoconstriction, 
inhibition and stimulation of smooth muscle cell proliferation and migration, thrombogenesis and fibrinolysis [4, 
5]. Certain circumstances that occur as a natural part of aging or additional perturbation (i.e. oxidative stress 
from consumption of a high-fat meal) can disturb the balance compromising the protective functions of the 
endothelium. The impairment of this vascular endothelium, or endothelial dysfunction leads to CVD [6-9]. 
 
It is well established that a high-fat meal (HFM) is a direct source of oxidative stress [10] and 
postprandial lipemia may represent an independent risk factor for atherosclerotic CVD. [11] The influx of free 
fatty acids (FFA) after a HFM leads to advanced oxidative stress, causing inhibition of nitric oxide (NO) 
production and bioavailability, which compromises the protection of the vasculature. Thus, postprandial 
oxidative stress from a HFM is proposed to be the source of endothelial impairment [11]. 
 
Correlations exist to support this connection [12]. More advanced research regarding a dose response 
among lipemia, oxidative stress and endothelial dysfunction is limited. There have been numerous studies that 
have compared the relationship between postprandial lipemia, oxidative stress, and endothelial function 
following a high-fat meal [6, 12-18], low-fat and high-fat meals [19-21], and even the effect of different lipid 
loads on triglycerides (TG) [22-24] and biomarkers of oxidative stress [24] . Tsai et al. [18] compared 
postprandial lipemia, oxidative stress, and endothelial function after a single meal consisting of 50% fat and 
found that triglycerides (TG) and oxidative stress increased at 2 and 4 hours postprandial, while endothelial 
function, as measured by flow-mediated dilation (FMD), decreased during the same time point. This 
demonstrates the correlations between lipemia, oxidative stress, and endothelial function but with only a single 
HFM. Cohen et al. [22] compared the effect of three HFMs consisting of 100 mL, 200 mL, and 300 mL of 
cream on TG response and found that TG response was different between each of the meals, with the meal 
 
consisting of 300 mL of cream having the largest TG response, and the peak to occur 2 hours postprandial. 
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Bloomer et al. [24]demonstrated a difference in TG and oxidative stress with two100% fat meals consisting of 
 
33 g and 66 g of cream, with both TG and oxidative stress being higher in the 66 g meal compared to the 33 g 
meal, but did not examine endothelial function. In order to investigate the relationship between lipemia, 
oxidative stress, and endothelial function, the dose response nature of isocaloric HFMs should be examined. 
Therefore, the purpose of this study was to investigate the dose response of three isocaloric HFM consisting 
of ~25%, ~50%, and ~75% fat on plasma TG, blood biomarkers of oxidative stress, and endothelial function. It 
was hypothesized that the highest fat load would produce the greatest amount of oxidative stress and 
endothelial dysfunction; whereas each lipid load would be significantly higher in TG, oxidative stress, and 
endothelial dysfunction than the previous. 
 
Methods 
 
 
Research Design 
 
 
The study was conducted in a randomized repeated measure design. Subjects consumed three 
separate meals consisting of 25%, 50%, and 75%, over a 7-14 day period, with at least 1-2 days between 
meals. Blood samples and brachial artery flow-mediated dilation (FMD) were performed before each meal and 
at 2:00 and 4:00 hours in the postprandial period. Blood samples were analyzed for plasma TG and 
biomarkers of oxidative stress, as measured by specifically 3-nitrotyrosine (3-NT) and thiobarbituric acid 
reactive substances (TBARS). The study design was approved by the University institutional review board. 
 
Subject Selection 
 
 
Ten young, healthy men were recruited, reviewed and signed the informed consent, and completed the 
study. All subjects participated in minimal physical activity (PA) (< 90 min/week) based upon previous research 
[25, 26]. The criterion for minimal PA was chosen to be less than the Surgeon General recommendation for 
individuals to participate in at least 150 minutes of physical activity weekly. All subject met the following criteria: 
were not lactose intolerant, no existing coronary artery disease, no existing diabetes, no existing pulmonary 
disease, not currently taking any vaso-active medications that might interfere with FMD measurements, not 
currently taking any cholesterol lowering medication (i.e. statins), normal cholesterol (<240 
5  
mg/dL) and/or triglycerides (<200 mg/dL),and no existing gallbladder disease. Subject descriptive 
demographic data are seen in Table 1. 
 
Study Procedure 
 
 
Each subject completed an initial screening phase before completing the three randomized high-fat 
challenge meals. 
 
i. Screening Phase 
 
 
The screening phase included a fasting blood draw, laboratory testing, completing a Medical History- 
Heath Habit Questionnaire, and completing a (3 month) Food Frequency Questionnaire (FFQ) (MSEL, 
Hutchinson Cancer Research Center, Nutrition Assessment Shared Resource, Seattle, WA). All subject 
completed the fasting blood draw at the IU Health Center to analyze for lipid profile. Height (cm), weight (kg), 
BMI (kg/m
2
) and waist circumference (cm) were collected for each subject. Waist circumference was 
 
measured using an inelastic vinyl tape measure (Creative Health Products, Ann Arbor, MI). The site for the 
waist was the horizontal plane, at the level of the narrowest part of the torso, between the 10
th 
rib and the iliac 
crest; with the subject standing erect, with relaxed abdomen, arms by the side, and feet together.  Three 
measurements were taken to the nearest 0.1 cm; the average of the three measurements was used to 
calculate the waist circumference. Variables of interest from the FFQ were energy intake (kcal/day); nutrient 
intake (total fat & saturated fat, carbohydrate & protein; g or percent of total caloric intake), and dietary 
antioxidants (E; IU & C; mg). 
 
ii. High-Fat Meal Challenge 
 
 
Subjects reported to the Clinical Exercise Physiology lab on three separate occasions and remained in 
the lab for 5-6 hours during each testing session. All subjects were instructed to fast for 12 hours and abstain 
from caffeine, vitamin supplements (including any antioxidant), and tobacco for 12 hours before reporting to 
the Clinical Exercise Physiology Laboratory. In addition, each subject was asked to abstain from physical 
activity/exercise 24 hours prior to the challenge meal. The meal the night prior to testing was not controlled. 
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The procedures for the high-fat meal challenge, brachial artery FMD, and repetitive blood draws are outlined 
below. 
 
a. Challenge Meals 
 
 
The high-fat meal was given between 6:00-9:00 am, depending on the subject’s schedule. All three 
meals were given at the same time for each subject. The composition of the three isocaloric meals are 
summarized in Table 2 and consisted of a mixture of Ensure®, Ensure Plus®, and heavy whipping cream and 
had a fat content of 25%, 50%, or 75%. The order of the meals was randomized for each subject. The subject 
was instructed to not eat anything except for the test meal during testing. Water was allowed ad libidum. 
 
b.   Brachial Artery FMD Procedure 
 
 
Brachial artery FMD was measured as previously described [27]. Subjects underwent an 
acclimatization phase (20 min) in order to obtain hemodynamic steady state by lying supine in a dark, climate 
controlled room (22-24
o
C), with their arms extended laterally. A Hokanson brachial artery cuff (Hokanson, 
Bellevue WA) was placed on the subject’s forearm to elicit brachial artery occlusion. The ultrasound image of 
the brachial artery was obtained longitudinally 2-10 cm above the antecubital fossa by 2D high resolution 
Terrason t3000 (Teratech Corporation, Burlington, MA) ultrasound system, using a 7 MHz linear transducer. 
Baseline brachial artery diameter and Doppler flow images were continuously recorded for 10 cardiac cycles 
(approx. 30 sec). Following baseline measurements, forearm occlusion will be elicited and maintained for 5 
minutes by inflating the cuff to 250 mmHg. After the 5 minute occlusion, the cuff was released and brachial 
artery diameter and Doppler flow images will be continuously recorded for an additional 3 minutes. The 
arterial diameters and blood flow velocity were identified and measured using the Vascular Analysis 
Integrative System and software (Medical Imaging Applications, Coralville, Iowa). The baseline artery 
diameter was compared to the maximal diameter found post-occlusion, in order to determine % change in 
dilation. The equation for calculating percent change in FMD is as follows: ((peak hyperemic diameter – 
baseline diameter) / (baseline diameter)) *100. 
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c. Repetitive Blood Draws 
 
 
Three blood draws were collected; baseline, and 2:00 and 4:00 hours post-meal. For the purpose of 
collecting plasma samples, IV access was obtained in the non-FMD arm or the back of the hand with a 22g 
oangiocath equipped with a PRN adapter and maintained for the duration of the treatment period. The IV 
access was flushed with normal saline (Hospira Pharmaceruticals). Venous blood samples (10-20 ml) were 
collected through the IV access and into ethylenediaminetetraacetic (EDTA) Vacutainer tubes (Vacutainer, 
Becton and Dickinson, Meylan, France) and separated by centrifugation within 30 minutes. Plasma was stored 
in 1.0 ml aliquots at -80
o 
C until analysis. 
 
 
The plasma samples were analyzed for blood biomarkers of oxidative stress, 3-NT and TBARS, and 
TG, using commercial assay kits. Standard curves for all assays were developed in order to determine the 
concentrations in the study samples. 3-NT was analyzed in plasma using a 3-Nitrotyrosine ELISA kit as 
described by the manufacture (Abcam, Cambridge, MA; ab116691). TBARS was analyzed in plasma using a 
commercial assay kit according to manufacture specification by determining the concentration of 
malodialdehyde (MDA) (Cayman Chemical, Ann Arbor, MI). TG was analyzed in plasma using a commercially 
available colorimetric kit (Cayman Chemical, Ann Arbor, MI). All assays were performed in duplicate on first 
thaw of the samples after being stored at -80
o
C. 
 
 
Statistical Analysis 
 
 
Descriptive statistics were used to analyze demographic data. Planned comparisons t-test were 
conducted in order to determine if there were differences in dependent variables among the meals of 25%, 
50%, and 75% fat. One-way repeated measure ANOVA was performed to analyze simple main effects 
between meals during measurements at baseline, 2 hours and 4 hours postprandial. When ANOVA was used 
to test a hypothesis, Tukey HSD was applied for follow-up to a significant F-ratio. Alpha level was set at p < 
0.05 for a two-tailed comparison. All statistical calculations were performed using SPSS 20.0 software (SPSS 
Inc., Chicago, Illinois, USA). 
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Results 
 
 
Subjects 
 
 
Complete data was collected on all 10 subjects, with the exception of blood data from two subjects at 
two separate time points. All subject reported participating in < 90 minutes of weekly physical activity, with 
most of their activity consisting of walking. The dietary data for all subjects during the three months prior to 
testing is shown in Table 3. The dietary intake for all subjects was consistent with current dietary 
recommendations of consuming approximately 2000 kcal/day, with 30-35% of those calories coming from fats. 
The recommended daily allowances (RDA) for vitamin E and C for men are 22.5 IU and 90 mg/day, 
respectively. No subjects were taking any vitamin supplements. 
 
Triglycerides 
 
 
TG for the three challenge meals is presented in Figure 3. TG were found to have a significantly 
higher concentrations with the 50% fat meal compared to the 25% fat meal (p = .001); but not between the 
other comparisons. A simple main effect was found between 25% and 50% fat meals at 2 hours postprandial 
(p = .000) but not for any of the other comparisons. 
 
Oxidative Stress 
 
 
Oxidative stress over the three challenge meals, as measured via TBARS assay, is presented in 
 
Figure 2. There were no statistically significant differences measured among any of the meals or time points (p 
 
> .05). Detectable 3-NT concentrations were found in only four out of the 10 subjects; therefore data was not 
analyzed or illustrated. 
 
Flow Mediated Dilation 
 
 
The baseline brachial artery diameters for the three challenge meals are displayed in Table 4. There 
were no significant differences in diameters among any of the meals or time points (p > .05). 
 
Data for pre- and postprandial FMD for the three challenge meals are presented in Figure 3. FMDs 
were found to have significantly lower values with the 50% fat meals compared to the 25% fat meal (p = .026), 
and the 75% fat meals compared to the 25% fat meal (p = .002); but not between the 50% and 75% fat meals 
(p = .142). A simple main effect was found at 2 hours postprandial between 25% and 75% fat meals (p = .027) 
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and at 4 hours postprandial between 25% and 50% (p = .017) and 25% and 75% fat meals (p = .013). 
 
 
Discussion 
 
 
The purpose of the study was to determine if there was a dose response between HFM on plasma 
TG, blood biomarkers of oxidative stress, and endothelial function. In the current study, we found that the only 
significant change in TG occurred during the 50% fat meal at 2 hours postprandial and no significant 
differences with the oxidative stress measures with any of the meals or time points. We also found that on 
consumption of a meal consisting of higher than 25% fat, that there is a significant decrease in endothelial 
function within 4 hours postprandial, as measured by FMD. However, the FMD response does not appear to 
be related to the TG response. Our finding may have been influenced by the 1) type of subject, 2) dose of lipid 
 
3) oxidative stress measurements and 4) measurement intervals. 
 
 
Our subjects were homogeneous. We required stricter inclusion/exclusion criteria than most studies 
 
[1, 6, 12, 14-17, 20-25, 28]. All subjects were young, healthy men with no significant differences in age, height, 
weight, BMI, or waist circumference. There also were no significant differences in diet three months prior to 
testing as measured by energy intake (kcal/day), nutrient intake (total fat, saturated fat, carbohydrate, and 
protein) or dietary antioxidants (vitamin E and C). All subjects underwent lipid profile screening to verify that 
they had normal lipid values due to hyperlipidemia potentially increasing the response of HFM. We also 
controlled for the possible beneficial effects of physical activity that have been seen with previous research 
[25, 26] by including only individuals who participated in < 90 minutes of physical activity per week. Women 
were specifically excluded from the study based upon men responding differently to HFM than women. 
Premenopausal women appear to have an inherent vascular protection from HFM independent of estradiol or 
progesterone levels [29]. In addition, our subject size was adequate and consistent with similar research 
studies [1, 6, 12-17, 19, 20, 24, 25, 28-42]. Power analysis was run and determined that we would need a 
sample size of at least 143 people in order to show a significant difference between the 50% and 75% meals 
with the calculated effect size of 0.28 from our data (data not shown). Given this information, we believe that in 
our subject homogeneous population of young inactive healthy men, did not compromise the outcome of the 
TG response. 
 
The proposed mechanism for endothelial dysfunction following a HFM is that an increase in TG leads 
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to increased oxidative stress which leads to decreased endothelial function. To detect a dose response for this 
mechanism, a dose response in TG needs to exist. However, no dose response was found for TG. The doses 
of lipids were chosen based the current literature. HFM with less than 40% fat did not exhibit any findings with 
TG, oxidative stress, and/or endothelial function [12, 40, 43, 44]. Therefore, we chose a dose of 50% to elicit a 
response to the HFM, the dose of 25% was chosen to be below 40% fat, and the dose of 75% was chosen to 
keep the same intervals in dose between meals. We also chose to control for potential confounding of calorie 
contents of each meal by having all meals isocaloric. Previous studies have that have investigated the effects 
of meals with different doses of lipids have not controlled for calories [22-24]. Therefore, it is unknown if the 
outcomes of these studies were based solely upon the different amounts of lipid and different caloric loads. No 
studies were found that have presented a dose of lipid in terms of percent total calories. It has been shown 
that different dietary fatty acids (stearic, palmitic, oleic, linoleic, etc.) can elicit different responses in lipid 
profile postprandial in young health men [45, 46]. In the current study, all fat content came from consumption 
of heavy whipping cream. Even with different amounts of fatty acids, the types of fatty acids would be 
consistent in each meal and should not affect the TG response. Perhaps the differences between doses 
should have been greater, such as 20%, 50%, and 80%, in order to see a dose response. Or perhaps the 
dose should have been in the magnitude of lipid with an increased in calories. On the other hand, when both 
calories and lipids are increased, the individual source (lipid or calories) for dysfunction cannot be identified. In 
any case, the 50% and 75% loads in our study were too close to demonstrate significant differences. Power 
analysis was run and determined we would need a sample size of 280 people to show significance between the 
25% and 75% meals with the calculated effect size of 0.22 from our data and 2867 people for the 50% and 
75% meals with the calculated effect size of 0.07 from our data (data not shown). This could also explain why 
there was not a dose response between oxidative stress and FMD. 
 
The methods used to measure oxidative stress have been controversial [47, 48]. The measurement of 
3-NT is appropriate for postprandial endothelial function studies due to it being an indirect marker of pro- 
oxidant peroxynitrite (ONOO
-
) [49, 50]. The oxidative stress from a HFM increases the production free 
 
- - -
 
radicals, specifically superoxide (O2 ), which reacts with NO to form ONOO . ONOO is a powerful oxidant 
 
capable of oxidizing low density lipoproteins [51], of causing vascular dysfunction [52] and is responsible for 
 
nitration of tyrosine residues in proteins [49]. Therefore, the presence of nitrotyrosine (NT) in the plasma is 
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considered to be an indirect measure of ONOO
- 
[49, 50]. Previous studies have successfully measured 3-NT 
in plasma samples [17, 50, 53, 54]. Thus, we chose to measure 3-NT due to the direct connection with 
vascular dysfunction. 
 
Even though differences in oxidative stress measurement were not found, both 3-NT and TBARS 
 
have been commonly used in other postprandial oxidative stress studies [10, 16, 17, 24, 25, 31-34, 36, 50, 53, 
 
54]. Several studies investigating postprandial oxidative stress have found changes in 3-NT within different 
subject population including normal controls [17, 50, 53], diabetes [17, 50, 53], and young lean healthy men 
[54]. 3-NT ELISA assays were used in all of these studies and were similar to the assay used in the current 
study. Yet, there are contractive studies [47, 48] showing that commercially available ELISA tests are not 
applicable for 3-NT determination in plasma samples due to technical issues and implausible results and that 
competitive luminescence assays are able to provide sufficient sensitivity and lead to clinically meaningful 
results. In the current study, we were only able to determine concentrations from a limited number of samples 
using 3-NT ELISA assay. It is possible that the ELISA used in our study was not a sensitive enough to 
determine changes in 3-NT in the plasma samples or the timing of the measurements missed the changes in 
oxidative stress. TBARS and/or MDA are also commonly used assay to determine postprandial oxidative 
stress and have been used previously in our lab [6, 12, 14, 24, 25, 32-34, 38, 39, 55-58]. In our study, there 
was no significant difference in TBARS found among the meals or time points. 
 
The timing of blood samplings was based upon previous research [6, 14, 15, 17, 24, 28, 30, 37, 59] 
shows the peaks in TG and oxidative stress postprandial occurred at 2 and 4 hours postprandial. The timing of 
samplings in these studies ranged from 30 minutes to 2 hour intervals over 4-6 hours postprandial. Even 
though our timing of sampling should detect the peaks in TG, oxidative stress, and endothelial function, it is 
possible that important data between these time points were not collected. In the current study, plasma TG 
peaked at 2 hours postprandial but only for the 50% meal, oxidative stress did not show any significant 
differences, and FMD showed the largest decreased at 4 hours with the 50% and 75% meals compared to 
25%. As discussed previously, the proposed mechanism is that a HFM leads to increased TG, increased 
oxidative stress, and decreased endothelial function. Therefore, TG and oxidative stress would increase to 
ultimately cause a decrease in endothelial function. Since we saw a decrease in FMD by 4 hours postprandial 
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in both 50% and 75% meals compared to 25%, we would assume that both TG and oxidative stress increased 
and could have missed the peak change due either incorrect timing of blood sampling or limited samples 
collected. 
 
Even though correlations between postprandial lipemia, oxidative stress, and endothelial function have 
been established, there is potentially another mechanism contributing to the results. In this study, there was a 
decrease in FMD at 4 hours postprandial with the 50% and 75% fat meals compared with the 25% fat meal, yet 
no significant differences in TG or measures of oxidative stress. Since there was a change in FMD, it is 
possible that another mechanism could be contributing to the change which is not related to TG or the 
measures of oxidative stress that we measured (3-NT and MDA). Another possible explanation is that the 
mechanism contributed to a localized effect on the endothelium that was not detected systemically in the 
plasma samples. The FFA from the meal could have led to a localized increase in oxidative stress within the 
endothelium that decreased NO bioavailability and subsequently lead to endothelial dysfunction. 
 
Continued research should consider the following: 1) using larger difference in doses of lipids between 
isocaloric meals to determine if there is a dose response with TG, oxidative stress, and endothelial function; 2) 
utilize different measurements of oxidative stress, such as competitive luminescence assays for 3-NT; and 3) 
collect more frequent measurements (such as every hour for 4 hours postprandial) to ensure the true peaks in 
measurements are being collected. 
 
Conclusion 
 
 
The current study found that young inactive healthy men, did not exhibit a dose response in TG for 
isocaloric HFMs consisting of 25%, 50%, and 75% fat. Perhaps the lipid load should be based on the amount 
of fat, not controlling for total calories, or larger differences in doses of lipids between the meals. Other 
measures of oxidative stress should be utilized before strong conclusions can be drawn. It should also be 
noted that even though there does not appear to be a dose response relationship of HFM, that eating meals 
consisting of 50% fat or higher does cause endothelial dysfunction, and should be avoided when possible. 
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Table 1. Demographics of the subjects 
 
 
 
Variable Value 
 
Age (yrs) 22.8 ± 2.9 
 
Height (cm) 175.0 ± 6.0 
 
Weight (kg) 72.80 ± 7.74 
 
BMI (kg/m
2
) 24 ± 2 
 
Waist Circumference (cm) 80.3 ± 4.8 
 
Physical activity (min/week) 69.5 ± 9.0 
 
Data presented as mean ± SD 
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Table 2. Composition of the three challenge meals 
 
 
 Meal 1 Meal 2 Meal 3 
Product 16 oz Ensure® 
 
8 oz Ensure Plus® 
14 oz Ensure Plus® 
 
2.7 oz Heavy W hipping 
 
Cream 
6 oz Ensure Plus® 
 
6 oz Heavy W hipping Cream 
Calories 850 kcal 860 kcal 863 kcal 
Percent Fat 25% 51% 76% 
Total Fat (g) 23.0 46.3 73.3 
Saturated fat (g) 3.0 20.7 42.8 
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Table 3. Dietary data for all subjects during the three months prior to testing 
 
 
Variable Value 
 
Kilocalories (kcal/day) 2011.1 ± 562.2 
 
Total fat (g) 76.9 ± 23.2 
 
Saturated fat (g) 27.1 ± 9.1 
 
Carbohydrate (g) 230.1 ± 77.5 
 
Protein (g) 79.7 ± 24.5 
 
Vitamin E (IU) 11.9 ± 3.7 
 
Vitamin C (mg) 97.1 ± 77.2 
 
Data presented as mean ± SD 
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Table 4. Baseline brachial artery diameters for the three challenge meals. 
 
 
Baseline diameters (mm) 
 
 25% 50% 75% 
Pre-meal 
 
2 hours 
 
4 hours 
3.98 ± 0.10 
 
3.99 ± 0.48 
 
3.94 ± 0.34 
4.00 ± 0.31 
 
4.02 ± 0.34 
 
4.00 ± 0.43 
4.08 ± 0.28 
 
3.98 ± 0.45 
 
3.98 ± 0.41 
Data presented as means ± SE. 
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Figure 1. Blood triglycerides before and following the consumption of three challenge meals in 
young health men. Data presented as mean ± SEM. *indicates significant difference (p < .05) 
compared to the 25% fat meal; # indicates a significant simple main effect (p < .05) for the meal 
compared to the 25% fat meal at the time point. 
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Figure 2. TBARS, as measured by malondialdehyde (MDA) concentration (uM), before and 
following the consumption of three challenge meals in young healthy men. Data presented as 
mean ± SEM. 
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Figure 3. Flow-mediated dilation (FMD) before and following the consumption of three challenge 
meals in young healthy men. Data presented as mean ± SEM. *indicates significant difference (p < 
.05) compared to the 25% fat meal; # indicates significant simple main effect (p < .05) for the meal 
compared to the 25% fat meal at the time point. 
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Appendix A - Review of Literature 
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Review of Literature 
 
 
I. Cardiovascular disease 
 
 
Atherosclerotic cardiovascular disease (CVD) is the leading cause of morbidity and mortality in 
western society and will soon become the pre-eminent health problem worldwide [1, 2]. Atherosclerosis is 
a progressive disease that begins in childhood, advances silently through a long preclinical stage, and 
eventually manifest clinically, typically from middle age in western societies. This disease involves 
inflammatory processes and is characterized by accumulation of lipids and fibrous elements within the 
vasculature that eventually leads to a clinical cardiac event. Over the past several decades, it has 
become clear that the initiation and progression of disease, and its later activation to increase the risk of 
morbid events, depends on profound dynamic changes in vascular biology [8, 60]. Therefore, research 
should focus on what causes these changes in vascular biology and how these changes can be 
prevented to help decrease the risk for atherosclerosis. 
 
There are numerous risk factors involved with atherosclerotic CVD. The risk of disease increases 
with age, due to the natural progression of the disease throughout life. Even though the disease affects 
both men and women, women have a decreased risk until menopause where their risk starts to increase 
due to a decreased production of estrogen [28]. Estrogen has been shown to protect the vasculature and 
decrease risk of CVD [31, 61, 62]. Other traditional risk factors that have been identified include smoking, 
physical inactivity, obesity, diabetes mellitus, high serum cholesterol concentrations, and high blood 
pressure. Some of the effects of obesity, physical inactivity, and diabetes mellitus are believed to be 
mediated by effects of insulin resistance, which influence a variety of metabolic factors associated with 
risk. However, a high proportion of the risk of CVD remains unexplained and recent research has focused 
on identifying novel risk factors to improve risk estimates and include: high C-reactive protein, a variety of 
measures of hemostatic function, arterial stiffness, endothelial dysfunction, inflammatory biomarkers and 
an exaggerated postprandial lipemic response following a high-fat meal [28]. Therefore, it is important 
that further research focuses on the connection between progression of CVD and these novel risk factors. 
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II. Endothelial function and dysfunction 
 
 
The endothelium has been identified as the key regulator of vascular homeostasis, due to it not 
only functioning as a barrier for the vessel but also acts as an active signal transducer for circulating 
influences that can modify vessel wall phenotype [3].  The endothelium acts to maintain the balance 
between vasodilation and vasoconstriction, inhibition and stimulation of smooth muscle cell proliferation 
and migration, and thrombogenesis and fibrinolysis [4, 5]. Certain circumstances that occur as a natural 
part of aging or additional perturbation (i.e. consumption of a high-fat meal), can disturb the balance. 
When this balance is upset, endothelial dysfunction occurs, causing damage to the arterial wall. 
Endothelial dysfunction is considered an early marker for atherosclerosis, preceding angiographic or 
ultrasound evidence of atherosclerotic plaque [5]. In order to understand the role of the endothelium in 
vascular disease and endothelial dysfunction, it is important to look at the normal vascular homeostasis 
along with progression to endothelial dysfunction. 
 
i. Normal vascular homeostasis 
 
 
The importance of the endothelium was first recognized by its effect on vascular tone. More 
recently, the normal, healthy endothelium has been found to regulate vascular tone, cellular adhesion, 
thromboresistance, smooth muscle cell proliferation and vessel wall proliferation. These functions protect 
the endothelium from atherogenic insult. [7, 63]. 
 
The endothelium produces and releases numerous vasoconstrictors and vasodilators. There are 
several vasoconstrictor substances which include endothelin and angiotensin II. Endothelin has been 
identified as the most potent endogenous vasoconstrictor [7]. Angiotensin II not only acts as a 
vasoconstrictor but is also a pro-oxidant [64] and stimulates production of endothelin. Endothelin and 
angiotensin II promote proliferation of smooth muscle cells and there by contribute to the formation of 
plaque [65]. Activated macrophages and vascular smooth muscle cells, characteristic cellular 
components of atherosclerotic plaque, produce large amounts of endothelin. 
 
There are also numerous vasodilator substances produced and released from the endothelium. 
The major vasodilator substance that is released from the endothelium is nitric oxide (NO). Other 
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endothelium-derived vasodilators include prostacyclin and bradykinin [65]. Prostacyclin acts 
synergistically with NO to inhibit platelet aggreagation [5]. Bradykinin stimulates release of NO, 
prostacyclin, and endothelium-derived hyperpolarizing factor, another vasodilator, which also contributes 
to inhibition of platelet aggreagation [65]. Bradykinin also stimulates production of tissue plasminogen 
activator (t-PA), and thus plays an important role in fibrinolysis. 
 
a.   Nitric Oxide (NO) 
 
 
Nitric oxide (NO) is a key endothelium-derived substance essential for normal vascular 
homeostasis. A defect in NO production or activity has been proposed as a major mechanism of 
endothelial dysfunction and a contributor to atherosclerosis [7]. Therefore, it is important to look at both 
the production and function of NO to understand the normal role for NO and what occurs during 
dysfunction. 
 
b. Production of NO 
 
 
Normal NO production within the vascular endothelial cell is depicted in the figure below [12]. NO 
is synthesized from L-arginine, molecular oxygen (O2), and electrons carried by NADPH and catalyzed via 
endothelial nitric oxide synthase (eNOS) and dependent on other cofactors (ex. tetrahydrobiopterin (BH4), 
flavin adenine dinucleonide (FAD) and flavin mononucleotide (FMN)). eNOS can be activated from shear 
stress from arterial blood flow, insulin, and small molecule agonists (ex. acetylcholine (ACh)). Insulin and 
shear stress work through calcium-independent signaling pathways that are mediated in part by 
phosphatidylinositol-3-kinase (PI-3 kinase), while ACh works through a calcium-dependent pathway [66]. 
29  
 
 
 
Figure 4. Normal nitric oxide production within the vascular endothelial cell. The precursors of NO 
include NADPH, L-arginine, and O2 and are catalyzed by eNOS and cofactors, including BH4. eNOS is 
activated by shear stress, insulin and acetylcholine increasing PI-3-kinase. Once NO is produced in the 
endothelium, it leaves the cell and allows for ant-adhesion, anti-coagulation, anti-fibronolysis and 
vasodilation. Reprinted from Wallace [12]. 
 
c. Function of NO 
 
 
NO mediates endothelium-dependent vasodilation by opposing the effects of endothelium-derived 
vasoconstrictors such as angiotensin II and endothelin. It also inhibits platelet adherence and 
aggregation, leukocyte adhesion/infiltration, and proliferation of vascular smooth muscle cells. NO 
prevents oxidative modification of low-density lipoprotein (LDL) cholesterol [67]. Oxidation of LDL has 
been proposed as a major mechanism of the atherosclerotic process [68]; furthermore, plasma and 
macrophage content of oxidized LDL in coronary plaques correlate with severity of acute coronary 
syndrome [69]. 
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Conversely, impaired production or activity of NO leads to events or action that promote 
atherosclerosis, such as vasoconstriction, platelet aggregation, smooth muscle cell proliferation and 
migration, leukocyte adhesion, and oxidative stress [70]. Oxidized LDL cholesterol increases synthesis of 
caveolin-1, which inhibits production of NO by inactivating eNOS [4]. NO normally inhibits platelet 
aggregation through a cyclic guanosine monophosphate (cGMP)- dependent mechanism along with 
inhibiting P-selectin expression on the platelet surface allowing for anti-coagulation [71, 72]. Thus, when 
NO bioavailability is decreased, it leads to a pro-coagulate environment and platelet aggregation. The 
increase in platelet aggregation also results in smooth muscle cell proliferation and migration along with 
vasoconstriction of the vessel. 
 
A decrease NO bioavailability also promotes leukocyte adhesion. Leukocytes are attracted to the 
activated endothelium through E-selectin and chemoattractants such as monocyte chemoattractant 
protein-1 (MCP-1).Once the leukocytes decrease speed, the leukocyte attaches to the endothelial surface 
due to intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). 
These cells can lead to atherosclerosis by evolving into macrophage and foam cells [73]. Oxidative stress 
can also interfere with the production and activity of NO by a number of mechanisms that are 
independent of LDL. For example, the free radical superoxide anion rapidly inactivates NO and destroys 
tetrahydrobiopterin (BH4), a cofactor required for NO synthesis [74]. 
 
ii. Endothelial dysfunction 
 
 
Endothelial dysfunction can be described as the reduction of the bioavailability of vasodilators, 
specifically NO, while endothelial-derived vasoconstrictors are increased [75]. This imbalance happens 
when damage occurs to the endothelium and initiates a number of events/processes that promote or 
exacerbate atherosclerosis. These include increased endothelial permeability, platelet aggregation, 
leukocyte adhesion, and generation of cytokines [60].Decreased production or activity of NO, manifested 
as impaired vasodilation, could possibly be the earliest signs of atherosclerosis. Given the relationship 
between endothelial dysfunction and CVD, the incidence of endothelial dysfunction may serve as a 
marker of unfavorable cardiovascular prognosis [76]. 
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a.   Oxidative stress 
 
 
Oxidative stress is considered a major mechanism involved in the pathogenesis of endothelial 
dysfunction and may serve as a common pathogenic mechanism of the effect of risk factors on the 
endothelium [77-79]. Oxidative stress occurs when reactive oxygen species (ROS) production is 
increased and/or antioxidant defenses are decreased. An important source of ROS is perhaps from the 
mitochondrion, where production of ROS and the dismuting capacity of mitochondrial superoxide 
dismutase (SOD) are carefully balanced during oxidative phosphorylation [80]. This balance can be 
disturbed during different situations, such as hypoxia, or conditions of increased substrate delivery, such 
as obesity related metabolic disorders or type II diabetes, which are characterized by hyperglycemia and 
hyperlipidemia [81, 82]. Other important sources of oxidative stress in the endothelium come from 
oxidases such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidases and xanthine oxidase, 
which have been shown on to have increased activity in arteries from patients with coronary disease [83, 
84]. 
 
 
Oxidative stress impacts endothelial function by reducing the endothelial production and 
bioavailability of NO, therefore promoting cellular damage and endothelial dysfunction. [78] When 
mitochondria within the endothelial cell produce ROS, in the form of superoxide (O 
-
) or hydrogen 
peroxide (H2O2), it interacts to block production and decrease bioavailability of NO. eNOS uncoupling can 
also occur where eNOS can generate ROS and results in O 
- 
formation if the cofactor BH  is not present, 
 
or generation of H2O2 if the substrate L-arginine is deficient [85]. Endothelial ROS signaling may be also 
be initiated by exposure to inflammatory cytokines and growth factors, and interaction of the endothelium 
with leukocytes [63]. Regardless of the source of oxidative stress, the interaction between ROS and NO 
sets up a vicious cycle, which results in further endothelial dysfunction and inflammation. 
 
iii. Measurements of endothelial function/dysfunction 
 
 
Since the discovery of importance of endothelial dysfunction in the progression of CVD, there 
have been numerous measurement techniques developed to be able to assess endothelial function. 
Ideally, the test should be safe, noninvasive, reproducible, repeatable, cost effective, and standardized 
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between laboratories. The results should also reflect the dynamic biology of the endothelium throughout 
the natural progression of atherosclerosis, define subclinical disease processes, as well as provide 
prognostic information for risk stratification in the later clinical phase. There is no single test that perfectly 
measures all these factors, yet some test are more useful at providing certain information than others 
[63]. Therefore, it depends on what information is trying to be obtained through testing as to which 
method to consider using. The table below lists the different methods of clinical assessment of endothelial 
function. 
 
Table 5. Methods of clinical assessment of endothelial function. Table constructed based on 
information from Farouque [86]. 
 
Methods of Clinical Assessment of Endothelial Function 
 
Vasodilatory Function Coagulation Biomarkers 
 
Cardiac catheterization von Willebrand Factor 
 
Venous occlusion plethysmography                                         Tissue type plasminogen activator (t-PA) 
Ultrasound flow-mediated dilation (FMD)                                  Plasminogen activator inhibitor-1 (PAI-1) 
Pulse wave analysis (PWA )                                                     Thrombomodulin 
Pulse contour analysis (PCA) Other Biomarkers 
 
Pulse amplitude tonometry (PAT) Asymmetric dimethylarginine (ADMA) 
 
Skin Macrovascular Iontophoresis High-sensitivity C-reactive protein (hs-CRP) 
 
Nitric Oxide Mediators Serum 
nitrates/nitrites (NOx) Soluble 
Adhesion Biomarkers 
Intercellular adhesion molecule-1 (ICAM-1) 
Vascular cell adhesion molecule-1 (VCAM-1) 
E-selectin 
P-selectin 
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Although there are many different methods to assess endothelial function, flow-mediated dilation 
(FMD) is the most frequently used method of analysis. FMD is currently the standard for noninvasive 
assessment of conduit artery endothelial function because there is clinical trial experience, validation, a 
firm link to biology, and association with cardiovascular events. FMD is measured through a noninvasive 
ultrasound-based test to assess conduit artery vascular function in the systemic circulation [87]. In order 
to understand the benefits to the technique, the procedure will be briefly outlined. The brachial artery 
diameter is measured before and after an increase in shear stress that is induced by reactive hyperemia. 
This is accomplished by placing a blood pressure cuff on the forearm distal to brachial artery and inflating 
the cuff to 200 mmHg or higher and releasing the cuff after 5 minutes. FMD occurs primarily as a result of 
local endothelial release of NO [88]. Brachial artery has been widely studied in clinical research and can 
be performed on almost any age group including children and the elderly. FMD also allows for testing of 
lifestyle and pharmacological interventions on the endothelial biology at a preclinical stage, when the 
disease is most likely reversible [89]. This testing can help researchers understand how the endothelium 
changes throughout the procession of diseases or acutely to an intervention. There are also recent 
guidelines that have been published to help standardize the measurements between laboratories [27]. 
 
III. Postprandial lipemia and oxidative stress 
 
 
In 1979, Zilversmit proposed that atherogenesis was a postprandial phenomenon and that 
chylomicrons or chylomicron remnants could cause atherosclerosis [90]. Since then, many studies have 
produced data supporting the atherogenic effects of postprandial lipoproteins. These studies have mainly 
compared postprandial responses of plasma lipoproteins in patients with different forms of atherosclerosis 
and in control subjects without vascular disease. The data from these studies has shown that 
postprandial lipoprotein abnormalities have been reported in both patients with advanced clinical signs of 
coronary heart disease or peripheral arterial disease and with people with early markers of vascular 
disease such as increased intima-media thickness. 
 
Postprandial lipemia is the result of an increase in circulating lipids in the bloodstream following a 
high-fat meal. Dietary fats consist mainly of triglycerides (TG) (90-98%) and are responsible for the 
majority of the increase in lipids in the postprandial lipemic response, with cholesterol and phospholipids 
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contribute only a small proportion. Therefore, the increase in plasma TG concentrations following a high- 
fat meal provides a good measure of postprandial lipemia. Any factor that affects the absorption, 
metabolism, and clearance of TG will have an effect on postprandial lipemia [28]. 
 
The average diet of North American men provides approximately 50-100 g of fat per day, 
consumed over 3-6 eating events [12]. Depending on the size and composition of the meal, the 
postprandial lipemic response can last up to 8 hours [91]. Thus, the typical North American diet results in 
a continuous state of postprandial lipemia. 
 
i. Mechanism of postprandial lipemia that increase risk of CVD 
 
 
Zilversmit was among the first to suggest that postprandial lipoproteins are involved in 
atherogenesis [90]. Numerous studies have shown that feeding animals meals high in fat produces 
cholesterol-rich chylomicron remnants, which are atherogenic. In a 1992 study by Patsch et al., they 
observed that patients with coronary artery disease showed a more prolonged and pronounced 
postprandial TG response to a dietary fat load compared with healthy individuals [92]. Since then, 
numerous studies have linked the postprandial increases in plasma TG concentrations with CVD via 
effects on atherosclerosis [93, 94], either directly through the atherogenic properties of chylomicron 
remnants, and/or indirectly by influencing compositional changes in other lipoproteins (LDL and HDL) 
involved in the process of atherosclerosis. Postprandial lipemia may also increase the risk of thrombosis 
by increasing the activation of factor VII (FVII), which promotes blood clotting, and by decreasing 
fibrinolytic activity, which promotes the breakdown of blood clots [95, 96]. 
 
a.   Lipoproteins 
 
 
Following the hydrolysis of chylomicron TG by lipoprotein lipase (LPL), there is an accumulation 
of chylomicron remnant particles in the circulation. These chylomicron remnants become cholesterol- 
enriched as a result of transfer of cholesteryl esters in exchange for TG from HDL by cholesteryl ester 
transfer protein (CETP). Cholesterol-enriched remnants have pro-inflammatory and pro-atherogenic 
properties and are considered atherogenic [92]. There is also some evidence to suggest that chylomicron 
and VLDL remnants (collectively termed TG Rich Lipoprotein (TRL) remnants) are toxic to endothelial 
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cells due to oxidative stress [97] and may be taken up directly by subendothelial macrophages to promote 
foam cell formation, which are lipid-filled cells that form fatty streaks on the arterial wall. Chylomicron 
remnants may also promote the differentiation of white blood cells (monocytes) into macrophages [98], 
which enhance the process of atherosclerosis via the formation of foam cells. This evidence suggests that 
chylomicron remnants but not TG-rich chylomicrons are atherogenic. Evidence to support the role of 
chylomicron remnants in CVD risk comes from patients with type III hyperlipidaemia, which results in 
increased concentration of chylomicron remnants and is associated with increased risk of CVD. In 
contrast, type I hyperlipidaemia is associated with elevated chylomicron TG concentrations but there is no 
increase associated with an increased CVD risk [44, 49, 50]. 
 
b.   Hemostatic function 
 
 
Postprandial lipemia may also increase CVD risk via its acute effect on hemostatic function. The 
hemostatic system is critical in maintaining the fluid properties of the blood; it includes the coagulation 
pathway,  platelets  and  the  fibrinolytic  system  [28].  There  is  evidence  from  animal  studies  that 
postprandial lipemia increases thrombosis. In humans, Meade et al. were the first to show that high 
plasma fibrinogen, FVII coagulant activity (FVIIc) and decreased fibrinolytic activity were associated with 
increased risk of fatal CVD in the Northwick Park Heart Study [99]. Since then, several other hemostatic 
risk factors for CVD have been identified and these include: activated factor XII, plasminogen activator 
inhibitor-1, von Willebrand factor and decreased concentrations of soluble thrombomodulin. The BNF 
Task Force Report [100] also identified prothrombin fragment 1 +2, factor IX activation peptide and fibrin 
D-dimer (a marker of fibrin turnover) as emerging hemostatic risk factors. 
 
Dietary lipids can affect hemostatic function in the long term and acutely after a high-fat meal [96]. 
Most studies investigating effects of dietary fat on hemostatic function have concentrated on their effects 
on the clotting factor FVII, as much of the variation in FVII levels is related to differences in fat intake. The 
major proportion of FVII circulates in the plasma in its inactive form (FVII). Cleavage of FVII generates the 
active form (FVIIa), which can now be measured using a specific and sensitive assay for FVIIa [101]. FVII 
coagulant activity (FVIIc) is a functional assay that measures both the inactive (FVII) and active (FVIIa) 
concentrations. It was found possible to produce large increases in FVIIa approximately 3-4 hours 
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following a meal [102]. This activation of FVII was not associated with an increase in the amount of 
circulating inactive FVII produced but the activation of it. Long-chain fatty acids cause an increase in 
FVIIa concentrations whilst short-chain and medium-chain fatty acids do not result in FVII activation [103, 
104]. Different fatty acids also appear to activate FVII acutely to different degrees, with the unsaturated 
fatty acid oleic acid, being a particularly potent activator of FVII in the immediate 3-6 hours following a 
meal [105, 106]. However, there are currently few studies that have investigated the acute effects of 
specific fatty acids on postprandial hemostatic factors, and more studies in this area together with the 
mechanisms linking dietary fat and hemostatic factors recommended by the BNF Task Force Report as a 
priority for future research [100]. 
 
The mechanism for this activation of FVII after a fatty meal is not fully understood. While there is 
a relationship between fasting plasma TG concentrations and total FVII (including the activated form) 
[107], there appears to be no clear relationship between the extent of postprandial lipemia and FVIIa 
[108, 109]. Furthermore, the importance of the postprandial increase in FVIIa on CVD risk is uncertain, as 
in the second Northwick Park Heart Study ad relationship between FVIIc and risk of CVD was not evident 
and FVIIa concentration (a more sensitive marker, which was not measured in the first study) was 
paradoxically associated with decreased risk [110]. However, in the second Northwick Park Heart Study, 
assessment of FVII was made at varying times of the day in non-fasting subjects, which will have affected 
FVII levels. Furthermore, fat intake in the study population had fallen considerably compared with the first 
Northwick Park Heart Study. However, it was shown among men that there was a large increment in 
FVIIa following a fatty meal high in oleic acid whereas FVIIa fell following a low-fat meal. As elevated 
FVIIa is associated with a hypercoaguable state, it was argued that it would be prudent for older subjects 
who are most at risk for CVD to avoid high intakes of fat in a single meal [106]. 
 
These postprandial changes in lipids, the hemostatic system, and endothelial function enhance 
the progression of CVD chronically via effects on atherosclerosis and have acute effects via the process 
of thrombosis. Any factor influencing the magnitude or duration of postprandial lipemia will therefore also 
have subsequent effects on CVD risk. 
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ii. Factors influencing postprandial lipemia 
 
 
The increase in plasma TG after consumption of a fatty meal is a function of gastric emptying, 
intestinal  absorption,  chylomicron  synthesis  and  secretion,  TG  lipolysis,  and  chylomicron  remnant 
removal [28]. Any factor that influences these functions will also affect the duration and magnitude of the 
postprandial response. Such factors include fasting TG concentrations, age, gender, apolipoprotein E 
genotype, weight, insulin sensitivity, LPL activity, apolipoprotein C-II, physical activity and diet. Although 
genetic variations (such an apolipoprotein E genotype and LPL deficiency) account for some variability 
observed between subjects in postprandial lipemic responses, most impaired lipemia is acquired due to 
factors such as diet and physical activity. 
 
a.   Physiological 
 
 
Age and sex can influence the postprandial lipid response, with women exhibiting a lower 
response at all ages, and younger subjects a lower response compared with older subjects [111]. There 
is also a relationship between fasting plasma TG concentrations and the level of lipemia, which is likely to 
be due to competition between VLDL and chylomicrons for LPL. When the effect of fasting plasma TG is 
taking into account, the effects of gender and age largely disappear [111]. 
 
Both chronic and acute exercise can also affect postprandial lipemia. Exercise training [111, 112] 
and physical activity within the 24 hours prior to a high-fat meal [26] reduces the postprandial lipemic 
response. Obesity is also associated with an exaggerated postprandial lipemia, but these effects are 
likely to be mediated through insulin resistance, rather than overall fat mass, because fat stores are 
proportionately greater in women than in men. But premenopausal women show a lower postprandial 
lipemic response compared with men. 
 
LPL activity is an independent predictor of postprandial TG [113] and may be the common factor 
in the differences in responses observed with age, sex, acute and chronic exercise and fasting TG 
concentrations. The activities of LPL are higher in young subjects compared with older subjects [114, 
115] and there is a tendency for higher LPL activity in women compared with men [116]. Furthermore, 
LPL  is  activated  by  insulin  and  is  found  bound  to  the  capillary  endothelium,  with  the  highest 
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concentrations in adipose tissue and muscle, where it functions to supply the underlying tissue with fatty 
acids derived from circulating chylomicron and VLDL. 
 
Insulin resistance has been shown to be positively correlated to postprandial TG concentrations 
[117], and is believed to be an important determinant of postprandial lipemia [118]. Insulin plays a 
fundamental role in lipolytic activity via its stimulatory effects on LPL and inhibitory effects on hormone 
sensitive lipase (HSL) activity. Insulin resistance is associated with dyslipidaemia characterized by high 
VLDL concentrations, impaired postprandial clearance of chylomicrons, low HDL cholesterol 
concentrations and a preponderance of dense LDL particles, all associated with an increased risk of 
CVD. The mechanism leading to this can be explained in terms of impaired LPL activity and a failure of 
insulin to suppress HSL and thus free fatty acid release from adipose tissue, resulting in increased 
hepatic TG synthesis and VLDL synthesis and secretion. The elevated VLDL concentrations in the 
circulation compete with chylomicrons for lipolysis by LPL and remnant removal and thus may prolong the 
postprandial response [70, 71]. 
 
b.   Dietary 
 
 
Dietary factors, particularly habitual dietary fat composition and the amount and type of fat in a 
meal are major determinants of the postprandial lipemic response. 
 
i.   Test meal fatty acid composition 
 
 
The magnitude of postprandial lipemia within an individual is directly proportional to the fat 
content of the meal [119]. Consecutive fat-containing meals also appear to enhance lipemia [114]. Short- 
and medium-chain SFA do not lead to significant lipemia [104, 120], because they are absorbed and 
transported via the hepatic portal vein. 
 
Trials have shown that n-3 polyunsaturated fatty acids (PUFA) produce a reduced postprandial 
response compared with those from a test meal containing SFA [120-125], probably by acutely 
suppressing VLDL synthesis and thus reducing competition from VLDL for removal of chylomicron 
remnants. Studies comparing monounsaturated fatty acids (MUFA) and SFA have reported conflicting 
results. An early view based on small studies, utilizing small fat loads, suggested that SFA might produce 
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a greater postprandial response than MUFA. It has since been reported that fats rich in oleic acids (such 
as high-oleic sunflower oil or olive oil) have been found to cause pronounced lipemia [105, 126], with a 
tendency for an early peak and larger chylomicron particles. There appears to be little difference in the 
postprandial lipemic response between cis- and trans-MUFA [103]. Very long-chain SFAs such as 
arachidic, behenic, and lignoceric acids are poorly absorbed and thus have little effect on postprandial 
lipemia. Variable results have been obtained with fats rich in the most commonly consumed SFAs: 
palmitic and stearic acid. Differences in postprandial responses following fats rich in palmitric and stearic 
acid are believed to be due to the position of these fatty acids with the TG molecule rather than the 
overall fatty acid composition [30]. 
 
Differences in postprandial lipemia produced following the consumption of different fatty acids 
may be due to their effects on intestinal chylomicron synthesis [127], chylomicron particle size [128], the 
rate of chylomicron TG lipolysis [129] and chylomicron remnant removal [130], all of which have been 
shown to be influenced by meal fatty acid composition. 
 
Other macronutrients within the test meal may also influence lipemia. While the protein content of 
a meal does not appear to influence postprandial lipemia [111], carbohydrates may affect the TG 
response. Indeed, it was recently reported that the presence of carbohydrate in a high-fat meal resulted in 
an insulin response that reduced the TG response compared with that with a low carbohydrate load [131]. 
 
ii.   Background dietary fatty acid composition 
 
 
Independent of any effect of the meal fatty acid composition, background dietary fatty acid 
composition also affects the postprandial TG response. The magnitude of postprandial lipemia is greatest 
following a background diet in SFA [123] while n-3 long-chain fatty acids attenuate the postprandial 
response to a standard fat meal [123, 124]. High intakes of long-chain n-6 fatty acids (linoleic acid) 
attenuate the postprandial response compared with SFA [123], but low additional intakes of linoleic acid 
(5 g/day) do not [132]. 
 
There appears to be no difference in postprandial lipemia following diets high in trans- or cis- 
 
MUFA [30]. A diet high in MUFA has been found to cause an early peak in plasma TG concentrations 
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[126]. Indeed, in 1998 Zampelas et al. [129] found that the pattern of lipemic response to identical meals 
was  different in  southern compared with  northern  Europeans and  that,  in  particular, subjects from 
southern Europe (who have a higher MUFA intake compared to northern Europeans) showed a marked 
early rise in TG with rapid return to fasting values, whereas northern Europeans showed a slow sluggish 
rise in TG which did not return to fasting values until 8 or 9 hours after the meal. Furthermore, Kelly et al. 
[133] in 2001 reported that there were no adverse effects of a high-MUFA diet on fasting hemostatic 
factors, and found that a background diet high in MUFA resulted in a reduced postprandial activation of 
FVIIa in response to a standard fat-containing meal. Few studies have examined the long-term effects of 
diet rich in specific SFAs on postprandial lipid metabolism. 
 
iii. How postprandial lipemia compromises protection and induces CVD. 
 
 
The influx of free fatty acids (FFA) after a high-fat meal leads to advanced oxidative stress, 
inhibition of NO production and bioavailability which compromises the protection of the vessels. In the 
postprandial state, there is an exaggerated influx of FFA into the muscle, adipose, and haptic tissue [134] 
as well as the vascular endothelial cells [135] resulting in FFA oxidation in the mitochondria. Increased β- 
oxidation and oxidation of FFA-derived acetyl CoA by the tricarboxylic acid cycle creates an 
overproduction of  electron donors (NADH and FADH2), thus  overloading the  mitochondrial electron 
transport chain (ETC). As a consequence, complex III of the ETC is blocked which causes accumulation 
 
of electrons in coenzyme Q. Since coenzyme Q donates electrons to molecular oxygen this generates 
 
- -
 
superoxide radicals (O2 ) [135]. The overproduction of O2 results in direct and indirect effect on vascular 
 
NO bioavailability. 
 
 
The resulting postprandial oxidative stress also triggers a number of atherogenic changes. These 
include increases in inflammation, sympathetic tone, vasoconstriction, thrombogenicity, and oxidation of 
low-density lipoprotein cholesterol [35, 136, 137]. The inflammatory nature of postprandial lipemia is 
demonstrated by immediate postprandial increases in C-reactive protein, cytokines, adhesion molecules, 
clotting factors, and endothelin-1. [16, 36]. 
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IV. High-fat meals: contribution to increased risk of CVD 
 
 
Research has shown that a high-fat meal is a direct source of oxidative stress [10] and 
postprandial lipemia may represent an independent risk factor for atherosclerotic CVD [11]. A high-fat 
meal leads to oxidative stress through an increase influx of free fatty acids (FFA) during the postprandial 
state. The FFA are broken down within the mitochondria via FFA oxidation. The increase in β-oxidation 
and oxidation of FFA-derived acetyl CoA by the tricarboxylic acid cycle creates an overproduction of 
electron donors (NADH and FADH2), which overloads the mitochondrial electron transport chain (ETC). 
This leads to blocking complex III of the ETC causing accumulation of electrons in coenzyme Q and leads 
 
- -
 
to the generation of superoxide radicals (O2 ) [12]. The overproduction of O2 results in direct and indirect 
 
effects on vascular NO bioavailability, leading to an increase in endothelial dysfunction.  The generation 
and effect of postprandial lipemia can be seen in the figures below. Based on the typical North American 
diet resulting in a continuous state of postprandial lipemia, the recurring postprandial oxidative stress 
initiates a nearly continuous cycle of endothelial dysfunction [9, 60] and leads to an increased risk factor 
for atherosclerotic CVD. 
 
 
 
 
Figure 5. Mitochondrial superoxide production during postprandial lipemia. (See above text for 
explanation). Reprinted from Wallace [12]. 
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Figure 6. Nitric oxide functions in the postprandial state leading to endothelial dysfunction. During 
 
postprandial lipemia, the increase in FFA generates O 
- 
from the mitochondria. O 
-
 interacts with NO to 
 
not only contribute to loss of NO bioavailability from endothelial function but it also results in formation of 
 
peroxynitrite (ONOO
-
). Furthermore, O and ONOO
- 
can oxidize BH , which leads to eNOS uncoupling. 
 
Uncoupled eNOS produces O 
- 
instead of NO, thus resulting in a vicious cycle.  Reprinted from Wallace 
 
[12] 
 
 
Even with all that is known about the effect of a high-fat meal on postprandial lipemia, oxidative 
stress, and endothelial function, there is a gap in knowledge. There have been numerous studies that 
have looked at the relationship between postprandial lipemia, oxidative stress, and endothelial function 
during a high-fat meal [12]and even studies that have compared low-fat and high-fat meals [19-21], but 
there is a lack of information as to the dose response nature of high-fat meals. In recent study by 
Bloomer et al. [24], two lipids meals of 33 g (300 kcal) and 66 g (600 kcal) were given to healthy young 
men and TG, malondialdehyde (MDA), and hydrogen peroxide (H2O2) were measured pre-meal and 30 
min, 1 hour, 2 hour, and 3 hour post-meal. The results showed that all values were higher after the 66 g 
43  
fat meal compared to the 33 g fat meal. The authors concluded that the magnitude of oxidative stress is 
dependent upon the amount of lipid consumed (66 g > 33 g). This study shows that there is an increase in 
oxidative stress with an increase in lipid consumption but still does not show if this occurs in a dose 
related fashion or the corresponding effect on endothelial function. 
 
 
The significance of determining a dose response of high-fat meals is to further understand how 
postprandial oxidative stress relates to endothelial function and to determine if there is a ceiling effect that 
occurs for ROS production and subsequent oxidative stress where consumption of a certain nutrients 
above a certain amount may not lead to further ROS production. From this information, better 
recommendation could be implemented guidelines that would help people at higher risk for 
atherosclerotic CVD make sure their consumption of fat was at a particular level. 
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Appendix B - Proposal 
 
 
 
 
 
 
 
Postprandial lipemia, oxidative stress, and endothelial 
function: a dose response 
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Introduction 
 
Atherosclerotic cardiovascular disease (CVD) is the leading cause of morbidity and mortality in 
western society and will soon become the pre-eminent health problem worldwide [1, 2]. Atherosclerosis 
originates in the inner most cellular lining of the artery, the endothelium. The endothelium is a key 
regulator of vascular homeostasis, due to it not only functioning as a barrier for the vessel but through 
antiatherogenic functions [3].  The endothelium acts to maintain the balance between vasodilation and 
vasoconstriction, inhibition and stimulation of smooth muscle cell proliferation and migration, and 
thrombogenesis and fibrinolysis [4, 5]. Certain circumstances that occur as a natural part of aging or 
additional perturbation (i.e. oxidative stress from consumption of a high-fat meal), can disturb the balance 
compromising the protective functions of the endothelium. The impairment of this vascular endothelium is 
called endothelial dysfunction and leads to CVD [6-9]. 
 
Research has shown that a high-fat meal is a direct source of oxidative stress [10] and 
postprandial lipemia may represent an independent risk factor for atherosclerotic CVD. The influx of free 
fatty acids (FFA) after a high-fat meal leads to advanced oxidative stress, along with inhibition of NO 
production and bioavailability, which compromises the protection of the vessels. Thus, postprandial 
oxidative stress from a high-fat meal is proposed to be the source of endothelial impairment [11]. Yet, 
there is a lack of research on the dose response nature of high-fat meals. The purpose of this study is to 
investigate the dose response relationship of three high-fat meals consisting of ~25%, ~50%, and ~75% 
fat on serum triglycerides (TG), blood biomarkers of oxidative stress, and endothelial function. It is 
hypothesized that the highest fat load will produce the greatest amount of oxidative stress and endothelial 
dysfunction. 
 
Research Design 
 
 
The study will be conducted as a randomized repeated measure design, along with subject 
blindness to the fat content of each meal. Subjects will consume three meals consisting of 25%, 51%, 
and 78%, over 7-10 days, with at least 1-2 days between meals. Blood samples and brachial artery flow- 
mediated dilation (FMD) will be performed before each meal and at 2:00 and 4:00 hours in the 
postprandial period. 
54  
I. Subject Selection 
 
 
Ten men and ten women who participate in minimal physical activity, between the ages of 18-40 
years old will be recruited for the study. Premenopausal women should have menstrual cycle duration 
between 25-35 days and should not be on any oral contraceptives based upon previous studies [31, 61, 
62]. Women subjects should also be studied between days 1-7 of their menstrual cycle due to hormone 
levels being more equivalent to men during this time of the menstrual cycle. Estrogen is known to be 
vasoprotective [31, 61, 62]. 
 
All subjects should participate in minimal physical activity based upon previous research [25, 26]. 
Research has shown that healthy individuals that are insufficiently active have a greater response to a 
high-fat meal compared to active individuals. The Surgeon General recommends individuals participate in 
at least 150 minutes of physical activity weekly. Therefore, in order to categorize subjects as insufficiently 
active, they should participate in 90 minutes or less of physical activity weekly. 
 
Due to the nature of the study, there are several criteria that could exclude potential subjects. 
These exclusion criteria include: lactose intolerance, existing coronary artery disease, existing diabetes, 
existing pulmonary disease, currently taking any vaso-active medications that might interfere with FMD 
measurements, currently taking any cholesterol lowering medication (i.e. statins), currently taking oral 
contraceptives, elevated cholesterol (>240 mg/dL) and/or triglycerides (>200 mg/dL),or gallbladder 
disease. 
 
II. Study Procedure 
 
 
 
Each subject will complete a screening phase before testing and three randomized high-fat meal 
treatments. The screening phase will include a fasting blood draw taken at the IU Health Center to 
exclude volunteers with high cholesterol and laboratory testing. After they qualify for the study and agree 
to participate, we will schedule the first meal challenge. All three meals should be consumed over a 7-10 
days, with at least 1-2 days between meals. For women, this needs to be sometime within days 1-7 of 
their menstrual cycle [31, 61, 62]. 
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i. Screening Phase 
 
a.   Fasting Blood Draw at IU Health Center (15-20 min) 
 
 
To exclude volunteers with high cholesterol, subjects will be asked to report to the laboratory of 
the IU Health Center for a fasting blood draw. The sample will be 20-45 ml (4-8 ½ teaspoons) of venous 
blood. Blood will be drawn by a certified technician via sterile techniques for cholesterol and triglycerides. 
The blood draw will be analyzed for lipid profile. 
 
The second part of the screening phase includes laboratory testing. Additional information 
collected as part of the screening process includes height, weight, Body Mass Index (BMI-kg/m
2
) and 
waist circumference. Subjects will also be asked to complete a Medical History-Heath Habit 
Questionnaire and a (3 month) Food Frequency Questionnaire. 
 
b.   Laboratory Testing (60-90 min) 
 
 
Additional information collected as part of the screening process before the three high-fat meal 
challenges includes height, weight, and waist circumference for each subject. Body Mass Index (kg/m
2
) 
will be calculated using height (m) measured to the nearest 0.1 cm (stadiometer (Holtain Limited, 
Crymych, UK)) and weight (kg) measured to the nearest 0.05 kg (Digital Scale (Sauter, Holbrook, MA)). 
Both height and weight will be taken without shoes and wearing as few clothes as possible. Waist 
circumference will be measured using an inelastic vinyl tape measure (Creative Health Products, Ann 
Arbor, MI). The site for the waist will be the horizontal plane, a the level of the narrowest part of the torso, 
between the 10
th 
rib and the iliac crest; with the subject standing erect, with relaxed abdomen, arms by 
the side, and feet together.  Three measurements will be taken to the nearest 0.1 cm; the average of the 
 
three measurements will be used to calculate the waist circumference. 
 
 
Subjects will also be asked to complete a Medical History-Health Habit Questionnaire and a (3 
month) food frequency questionnaire. The Medical History – Health Habit Questionnaire is comprised of 
questions on hospitalization, medications, family history and risk factors for coronary heart disease. A (3 
month) food frequency questionnaire (MSEL & GSEL, Hutchinson Cancer Research Center, Nutrition 
Assessment Shared Resource, Seattle, WA) will be completed by subjects during screening. Variables of 
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interest will be energy intake (kcal/day); nutrient intake (total fat & saturated fat, carbohydrate & protein; g 
or mg or percent of total caloric intake), and dietary antioxidants (E & C; mg). If the subject does not 
qualify for the study they will have the opportunity to receive their testing results and all information will be 
destroyed. 
 
ii.   High-Fat Meal Challenge 
 
 
Subjects will report to the Clinical Exercise Physiology lab on three separate occasions and will 
be expected to stay at the lab for 5-6 hours during testing. All subjects will be instructed to fast for 12 
hours and abstain from caffeine, vitamin supplements (including any antioxidant), and tobacco for 12 
hours before reporting to the Clinical Exercise Physiology Laboratory. In addition, each subject will be 
asked to abstain from physical activity/exercise 24 hours prior to the challenge meal. The procedures for 
the high-fat meal challenge, brachial artery FMD, and repetitive blood draws are outlined below. 
 
a. Challenge Meals 
 
 
The high-fat meal will be given between 6:00-9:00 am, depending on the subject’s schedule. The 
three meals are summarized in Table 1 and will consist of a mixture of Ensure, Ensure Plus, and heavy 
whipping cream and will have a fat content of 25%, 51%, or 78%. The flavor of Ensure will be chosen by 
each subject. The order of the meals will be randomized for each subject, with the subject being blinded 
to the fat content of each meal. The meals will be prepared in the Metabolic Kitchen of the Human 
Performance labs prior to ingestion. The blender will be cleaned and sterilized between meals. The 
subject will not be allowed to eat anything except for the test meal during testing. Water will be allowed ad 
libidum. 
 
 
 Meal 1 Meal 2 Meal 3 
Product 16 oz Ensure 
8 oz Ensure Plus 
14 oz Ensure Plus 
2.7 oz Heavy Whipping 
Cream 
6 oz Ensure Plus 
6 oz Heavy Whipping Cream 
Calories 850 kcal 860 kcal 863 kcal 
Percent 
Fat 
25% 51% 78% 
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b.   Brachial Artery FMD 
 
 
Brachial artery FMD will be measured as previously described [27]. Subjects will undergo an 
acclimatization phase (20 min) in order to obtain hemodynamic steady state by lying supine in a dark, 
climate controlled room (22-24
o
C), with their arms extended laterally. A Hokanson brachial artery cuff 
(Hokanson, Bellevue WA) will be placed on the subject’s forearm to elicit brachial artery occlusion. The 
ultrasound image of the brachial artery will be obtained longitudinally 2-10 cm above the antecubital fossa 
by 2D high resolution Terrason t3000 (Teratech Corporation, Burlington, MA) ultrasound system, using a 
7 MHz linear transducer. Baseline brachial artery diameter and Doppler flow images will be continuously 
recorded for 10 cardiac cycles (approx. 30 sec). Following baseline measurements, forearm occlusion will 
be elicited and maintained for 5 minutes by inflating the cuff to 250 mmHg. After the 5 minute occlusion, 
the cuff will be released and brachial artery diameter and Doppler flow images will be continuously 
recorded for an additional 3 minutes. The arterial diameters and blood flow velocity will be identified and 
measured using the Vascular Analysis Integrative System and software (Medical Imaging Applications, 
Coralville, Iowa). The baseline artery diameter will be compared to the maximal diameter found post 
occlusion, in order to determine % change in dilation.  The equation for calculating percent change in 
FMD is as follows: ((peak hyperemic diameter – baseline diameter) / (baseline diameter)) *100. 
 
c.   Repetitive Blood Draws 
 
 
Three blood draws will be collected; baseline, and 2:00 and 4:00 hours post-meal. For the 
purpose of collecting plasma samples, IV access will be obtained in the non-FMD arm or the back of the 
hand with a 22g or 24 g angiocath equipped with a PRN adapter and maintained for the duration of the 
treatment period. The IV access will be flushed with normal saline (Hospira Pharmaceruticals). Venous 
blood samples (10-20 ml) will be collected through the IV access and immediately transferred to 
ethylenediaminetetraacetic (EDTA) Vacutainer tubes (Vacutainer, Becton and Dickinson, Meylan, France) 
and separated by centrifugation within 30 minutes. Plasma will be stored in 1.0 ml aliquots at -80
o 
C until 
 
analysis. The plasma samples will be analyzed for TG, blood biomarkers of oxidative stress such as 
nitrotyrosine (NT), and total antioxidant capacity, using commercial assay kits. 
58  
iii.  Statistical Analysis 
 
 
Descriptive statistics will be used to analyze demographic data. The statistical data will be 
compared using two-way repeated measures ANOVA. The postprandial brachial artery FMD variable 
used for this analysis will be calculated as the area under the curve (AUC); using the baseline and the 
four hour response. Each area will be calculated as the sum of triangles and rectangles corresponding to 
each measurement. By using the AUC, it will give us the total volume of the responses. When ANOVA is 
used to test a hypothesis, Tukey HSD will be applied for follow-up to a significant F-ratio. Alpha level will 
be set at p < 0.05 for a two-tailed comparison. 
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Table 6. Demographic data for all subjects who completed the study. 
 
 
Subject  IC 
 
Status 
 
Sex 
 
008 
 
Age 
 
Height (em) 
 
Height (m) 
 
Weight (kg) 
 
BMI 
Waist 
(em) 
 
PA (min/vvk) 
R3162 Complete M 6/15/1991 20.5 178.5 1.79 83.52 26 83.0 60.0 
R3163 Complete M 4/1/1990 21.8 174.0 1.74 64.78 21 74.0 85.0 
R3165 Complete M 5/9/1986 25.8 167.9 1.68 65.38 23 79.0 60.0 
R3166 Complete M 2/2/1991 21.1 162.9 1.63 66.08 25 78.0 65.0 
R3167 Complete M 9/14/1991 20.5 178.6 1.79 65.41 21 75.0 75.0 
R3170 Complete M 6/13/1983 28.8 180.1 1.80 85.52 26 88.5 75.0 
R3171 Complete M 11/26/1989 22.3 176.4 1.76 78.10 25 82.0 70.0 
R3174 Complete M 6/24/1992 19.9 179.2 1.79 74.97 23 79.0 80.0 
R3177 Complete M 8/20/1986 25.7 181.2 1.81 70.01 21 77.0 65.0 
R3179 Complete M 3/2711990 22.2 170.8 1.708 74.27 25 87.0 60.0 
Average    22.8 175.0 1.75 72.80 24 80.3 69.5 
St Dev    2.9 6.0 0.06 7.74 2 4.8 9.0 
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Table7. Blood triglycerideconcentrations(mg/dL)for all subjects beforeand followingconsumption of three 
challenge meals. Missing data for R3170at 25_4and R3179at75_base,75_2,and 75_4dueto inability to draw blood at 
those ti me points. 
 
 TG (rJ9dL) 
 25_base 25_2 25_4 50_base 50_2 50_4 75_base 75_2 75_4 
R3162 77 128 67 56 209 97 50 341 219 
R3163 36 77 59 60 162 99 36 108 68 
R3165 261 212 112 253 292 266 130 207 347 
R3166 25 28 25 20 33 22 32 57 38 
R3167 41 45 40 30 115 40 41 69 60 
R3170 56 105 NA 54 136 63 35 150 154 1 
R3171 69 90 76 63 161 90 53 144 100 
R3174 61 238 97 40 328 208 61 223 218 
R3177 59 126 112 71 151 67 47 85 102  1 
R3179 76 161 283 144 353 502 NA NA NA 
Average 76 121 97 79 194 145 54 154 145 
St Dev 18 63 81 36 101 148 10 95 70 
St Error 6 20 26 11 32 47 3 30 22 
 7
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Table 8. TBARS, as measured by malondialdehyde (MDA), concentration (umoi/L) for all subjects before and 
following consumption of three challenge meals. Missing  data for R3170 at 25_4 and R3179 at 75_base, 75_2, and 75_4 
due to inability to draw blood at those time points. 
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Table 9. Flow-mediated dilation (FMD), as measured by a percent  change from baseline(%), for all subjects 
before and following consumption of three challenge meals. 
 
FMD (%) 
 25  base 25 2 25 4 50  base 50  2 50  4 75  base 75  2 75  4 
R3162 6.13 7.91 6.9 9.59 7.97 6.21 7.21 3.06 9.25 
R3163 5.88 4.68 6.59 5.52 4.79 4.6 7.31 3.56 3.46 
R3165 10.89 9.8 11.78 9.25 7.7 5.37 9.94 6.64 6.06 
R3166 8.26 6.0 4.39 5.28 2.49 5.75 6.54 7.75 4.65 
R3167 10.18 10.95 9.97 11.13 6.81 7.79 12.68 9.87 7.7 
R3170 6.83 5.79 5.26 6.26 5.65 4.38 4.55 5.84 3.08 
R3171 7.77 7.36 8.02 6.61 8.46 7.67 5.81 3.89 6.83 
R3174 3.21 3.81 5.77 5.73 4.28 2.3 6.3 3.92 1.65 
R3177 7.01 3.85 7.64 5.69 3.69 4.64 2.75 0.8 0.81 
R3179 7.15 10.98 9.71 10.89 6.86 7.85 7.02 9.1 2.24 
Average 7.33 7.11 7.60 7.60 5.87 5.66 7.01 5.44 4.57 
so 2.18 2.75 2.32 2.35 2.01 1.79 2.73 2.89 2.80 
SE 0.69 0.87 0.73 0.74 0.63 0.57 0.86 0.92 0.89 
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Table 10. Flow-mediated dilation (FMD) baseline diameters (mm) for all subjects before and following consumption of three 
challenge meals. 
 
FMD Baseline Diameter 
 25  base 25  2 25  4 50  base 50  2 50  4 75  base 75  2 75  4 
R3162 3.85 3.85 3.99 4.32 3.94 3.91 4.50 4.00 3.72 
R3163 4.17 4.21 4.08 3.77 3.86 4.00 4.01 4.09 4.05 
R3165 3.74 3.74 3.65 3.86 3.96 3.94 3.85 3.91 4.02 
R3166 3.63 3.82 3.78 3.83 3.66 3.78 3.80 3.49 3.69 
R3167 3.80 3.60 3.88 3.86 3.68 3.70 3.82 3.54 3.90 
R3170 4.03 4.09 4.06 4.05 4.23 4.35 4.29 4.19 4.02 
R3171 3.85 3.67 3.71 3.98 4.20 3.53 3.74 3.66 3.63 
R3174 4.79 5.25 4.82 4.73 4.76 5.04 4.45 4.95 5.04 
R3177 3.87 3.82 3.78 3.94 4.21 4.03 4.24 4.34 4.04 
R3179 4.09 3.83 3.68 3.69 3.68 3.67 4.07 3.62 3.69 
Mean 3.98 3.99 3.94 4.00 4.02 4.00 4.08 3.98 3.98 
so 0.33 0.48 0.34 0.31 0.34 0.43 0.28 0.45 0.41 
SE 0.10 0.15 0.11 0.10 0.11 0.14 0.09 0.14 0.13 
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Table 11. Flow-mediated dilation (FMD) peak diameters (mm) for all subjects before and following consumption of 
three challenge meals. 
 
FMD Peak Diameter - I 
 25  base 25 2 25  4 50  base 50  2 50  4 75 base 75  2 75 4 
R3162 4.09 4.15 4.26 4.73 4.26 4.15 4.82 4.12 4.07 
R3163 4.42 4.40 4.35 3.98 4.04 4.18 4.30 4.09 4.19 
R3165 4.15 4.11 4.08 4.21 4.26 4.15 4.23 4.17 4.27 
R3166 3.94 4.05 3.95 4.03 3.76 4.00 4.05 3.76 3.87 
R3167 4.19 3.99 4.27 4.29 3.93 3.99 4.31 3.89 4.20 
R3170 4.31 4.33 4.27 4.31 4.47 4.54 4.49 4.44 4.15 
R3171 4.15 3.94 4.01 4.25 4.55 3.80 3.96 3.80 3.88 
R3174 4.94 5.46 5.10 5.00 4.96 5.15 4.73 5.14 5.12 
R3177 4.14 3.97 4.07 4.16 4.36 4.22 4.36 4.38 4.07 
R3179 4.38 4.25 4.03 4.10 3.93 3.95 4.36 3.95 3.77 
Mean 4.27 4.27 4.24 4.31 4.25 4.21 4.36 4.17 4.16 
so 0.27 0.45 0.33 0.32 0.36 0.38 0.27 0.41 0.38 
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Appendix D - Statistics 
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GET 
 
FILE='E:\Documents\Thesis (Lipid Load)\SPSS\TG Data.sav'. 
DATASET NAME DataSet2 WINDOW=FRONT. 
DATASET ACTIVATE DataSet1. 
DATASET CLOSE DataSet2. 
GET 
FILE='E:\Documents\Thesis (Lipid Load)\SPSS\TG Data.sav'. 
DATASET NAME DataSet3 WINDOW=FRONT. 
DATASET ACTIVATE DataSet3. 
 
SAVE OUTFILE='E:\Documents\Thesis (Lipid Load)\SPSS\TG Data.sav' 
 
/COMPRESSED. 
 
GLM TG_25_B TG_50_B TG_75_B 
 
/WSFACTOR=Meals 3 Polynomial 
 
/METHOD=SSTYPE(3) 
 
/EMMEANS=TABLES(Meals) COMPARE ADJ(LSD) 
 
/PRINT=DESCRIPTIVE ETASQ OPOWER 
 
/CRITERIA=ALPHA(.05) 
 
/WSDESIGN=Meals. 
 
General Linear Model- one-way repeated measures ANOVA for TG at baseline 
[DataSet3] E:\Documents\Thesis (Lipid Load)\SPSS\TG Data.sav 
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Within-Subjects Factors 
 
 
Measure:   MEASURE_1 
 
 
Meals 
 
Dependent 
 
Variable 
 
1 
 
 
2 
 
 
3 
 
TG_25_B 
TG_50_B 
TG_75_B 
 
 
 
Descriptive Statistics 
 
 
 
Mean 
 
Std. Deviation 
 
N 
 
TG_25_B 
TG_50_B 
TG_75_B 
 
76.11 
 
 
71.89 
 
 
53.89 
 
71.252 
 
 
69.874 
 
 
30.060 
 
9 
 
 
9 
 
 
9 
 
 
 
Multivariate Tests
a
 
 
 
Effect 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meals 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.266 1.267
b
 
 
2.000 
 
7.000 
 
.339 
 
.734 1.267
b
 
 
2.000 
 
7.000 
 
.339 
 
.362 1.267
b
 
 
2.000 
 
7.000 
 
.339 
 
.362 1.267
b
 
 
2.000 
 
7.000 
 
.339 
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Multivariate Tests
a
 
 
 
Effect 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meals 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.266 2.534
b
 
 
.194 
 
.266 2.534
b
 
 
.194 
 
.266 2.534
b
 
 
.194 
 
.266 2.534
b
 
 
.194 
 
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meals 
b. Exact statistic 
c. Computed using alpha = .05 
 
 
 
 
Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Mauchly's W 
 
Approx. Chi- 
Square 
 
df 
 
Sig. Epsilon
b
 
 
Greenhouse- 
Geisser 
 
Meals 
 
.304 
 
8.334 
 
2 
 
.015 
 
.590 
 
 
Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Epsilon 
 
Huynh-Feldt 
 
Lower-bound 
 
Meals 
 
.631 
 
.500 
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Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix.
a
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meals 
 
 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are 
displayed in the Tests of Within-Subjects Effects table. 
 
 
 
 
Tests of Within-Subjects Effects 
 
 
Measure:   MEASURE_1 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Meals 
Huynh-Feldt 
 
 
Lower-bound 
 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Error(Meals) 
Huynh-Feldt 
 
 
Lower-bound 
 
2506.963 
 
2 
 
1253.481 
 
1.967 
 
.172 
 
2506.963 
 
1.179 
 
2125.847 
 
1.967 
 
.195 
 
2506.963 
 
1.263 
 
1985.175 
 
1.967 
 
.193 
 
2506.963 
 
 
10198.370 
 
1.000 
 
 
16 
 
2506.963 
 
 
637.398 
 
1.967 
 
.198 
 
10198.370 
 
9.434 
 
1080.998   
 
10198.370 
 
10.103 
 
1009.466   
 
10198.370 
 
8.000 
 
1274.796   
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Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Meals 
Huynh-Feldt Lower-
bound Sphericity 
Assumed 
Greenhouse-Geisser 
Error(Meals) 
Huynh-Feldt 
 
 
Lower-bound 
 
.197 
 
3.933 
 
.346 
 
.197 
 
2.319 
 
.257 
 
.197 
 
2.483 
 
.267 
 
.197 
 
1.967 
 
.236 
   
   
   
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meals 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Linear 
Meals 
Quadratic 
 
 
Linear 
Error(Meals) 
Quadratic 
 
2222.222 
 
1 
 
2222.222 
 
2.480 
 
.154 
 
284.741 
 
 
7167.778 
 
1 
 
 
8 
 
284.741 
 
 
895.972 
 
.752 
 
.411 
 
3030.593 
 
8 
 
378.824   
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Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meals 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Linear 
Meals 
Quadratic 
 
 
Linear 
Error(Meals) 
Quadratic 
 
.237 
 
2.480 
 
.284 
 
.086 
 
.752 
 
.120 
   
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Intercept 
 
 
Error 
 
122277.370 
 
 
76704.296 
 
1 
 
 
8 
 
122277.370 
 
 
9588.037 
 
12.753 
 
.007 
 
.615 
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Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Noncent. Parameter 
 
Observed Power 
 
Intercept 
 
 
Error 
 
12.753 
 
.877 
 
 
 
a. Computed using alpha = .05 
 
Estimated Marginal Means 
 
Meals 
 
 
Estimates 
 
 
Measure:   MEASURE_1 
 
 
Meals 
 
Mean 
 
Std. Error 
 
95% Confidence Interval 
 
Lower Bound 
 
Upper Bound 
 
1 
 
 
2 
 
 
3 
 
76.111 
 
 
71.889 
 
 
53.889 
 
23.751 
 
 
23.291 
 
 
10.020 
 
21.342 
 
 
18.179 
 
 
30.783 
 
130.880 
 
 
125.599 
 
 
76.995 
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Pairwise Comparisons 
 
Measure:   MEASURE_1 
 
 
(I) Meals (J) Meals 
 
Mean Difference 
 
(I-J) 
 
Std. Error Sig.
a
 
 
95% Confidence Interval for 
Difference
a
 
 
Lower Bound 
 
Upper Bound 
 
2 
1 
3 
 
 
1 
2 
3 
 
 
1 
3 
2 
 
4.222 
 
4.847 
 
.409 
 
-6.955 
 
15.400 
 
22.222 
 
 
-4.222 
 
 
18.000 
 
 
-22.222 
 
14.110 
 
 
4.847 
 
 
14.224 
 
 
14.110 
 
.154 
 
 
.409 
 
 
.241 
 
 
.154 
 
-10.317 
 
 
-15.400 
 
 
-14.802 
 
 
-54.761 
 
54.761 
 
 
6.955 
 
 
50.802 
 
 
10.317 
 
-18.000 
 
14.224 
 
.241 
 
-50.802 
 
14.802 
 
 
 
Based on estimated marginal means 
 
 
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
 
 
 
 
 
Multivariate Tests 
 
 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
.266 
 
 
.734 
 
 
.362 
 
 
.362 
1.267
a
 
 
1.267
a
 
 
1.267
a
 
 
1.267
a
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
7.000 
 
 
7.000 
 
 
7.000 
 
 
7.000 
 
.339 
 
 
.339 
 
 
.339 
 
 
.339 
 
.266 
 
 
.266 
 
 
.266 
 
 
.266 
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Multivariate Tests 
 
 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
2.534 
 
 
2.534 
 
 
2.534 
 
 
2.534 
.194
a
 
 
.194
a
 
 
.194
a
 
 
.194
a
 
 
 
 
Each F tests the multivariate effect of Meals. These tests are based on the linearly independent pairwise 
comparisons among the estimated marginal means. 
 
a. Exact statistic 
 
 
b. Computed using alpha = .05 
 
GLM TG_25_2 TG_50_2 TG_75_2 
 
/WSFACTOR=Meals 3 Polynomial 
 
/METHOD=SSTYPE(3) 
 
/EMMEANS=TABLES(Meals) COMPARE ADJ(LSD) 
 
/PRINT=DESCRIPTIVE ETASQ OPOWER 
 
/CRITERIA=ALPHA(.05) 
 
/WSDESIGN=Meals. 
 
General Linear Model- one-way repeated measures ANOVA for TG at 2 hrs 
[DataSet3] E:\Documents\Thesis (Lipid Load)\SPSS\TG Data.sav 
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Within-Subjects Factors 
 
 
Measure:   MEASURE_1 
 
 
Meals 
 
Dependent 
 
Variable 
 
1 
 
 
2 
 
 
3 
 
TG_25_2 
 
 
TG_50_2 
 
 
TG_75_2 
 
 
 
Descriptive Statistics 
 
 
 
Mean 
 
Std. Deviation 
 
N 
 
TG_25_2 
 
 
TG_50_2 
 
 
TG_75_2 
 
116.56 
 
 
176.33 
 
 
153.78 
 
70.218 
 
 
89.766 
 
 
90.943 
 
9 
 
 
9 
 
 
9 
 
 
 
Multivariate Tests
a
 
 
 
Effect 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meals 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.807 14.681
b
 
 
2.000 
 
7.000 
 
.003 
 
.193 14.681
b
 
 
2.000 
 
7.000 
 
.003 
 
4.194 14.681
b
 
 
2.000 
 
7.000 
 
.003 
 
4.194 14.681
b
 
 
2.000 
 
7.000 
 
.003 
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Multivariate Tests
a
 
 
 
Effect 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meals 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.807 29.361
b
 
 
.975 
 
.807 29.361
b
 
 
.975 
 
.807 29.361
b
 
 
.975 
 
.807 29.361
b
 
 
.975 
 
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meals 
b. Exact statistic 
c. Computed using alpha = .05 
 
 
 
 
Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Mauchly's W 
 
Approx. Chi- 
Square 
 
df 
 
Sig. Epsilon
b
 
 
Greenhouse- 
Geisser 
 
Meals 
 
.440 
 
5.739 
 
2 
 
.057 
 
.641 
 
 
Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Epsilon 
 
Huynh-Feldt 
 
Lower-bound 
 
Meals 
 
.710 
 
.500 
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Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix.
a
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meals 
 
 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are 
displayed in the Tests of Within-Subjects Effects table. 
 
 
 
 
Tests of Within-Subjects Effects 
 
 
Measure:   MEASURE_1 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Meals 
Huynh-Feldt 
 
 
Lower-bound 
 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Error(Meals) 
Huynh-Feldt 
 
 
Lower-bound 
 
16402.889 
 
2 
 
8201.444 
 
4.308 
 
.032 
 
16402.889 
 
1.282 
 
12790.313 
 
4.308 
 
.057 
 
16402.889 
 
1.420 
 
11547.590 
 
4.308 
 
.051 
 
16402.889 
 
 
30457.111 
 
1.000 
 
 
16 
 
16402.889 
 
 
1903.569 
 
4.308 
 
.072 
 
30457.111 
 
10.260 
 
2968.654   
 
30457.111 
 
11.364 
 
2680.216   
 
30457.111 
 
8.000 
 
3807.139   
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Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Meals 
Huynh-Feldt Lower-
bound Sphericity 
Assumed 
Greenhouse-Geisser 
Error(Meals) 
Huynh-Feldt 
 
 
Lower-bound 
 
.350 
 
8.617 
 
.663 
 
.350 
 
5.525 
 
.517 
 
.350 
 
6.120 
 
.549 
 
.350 
 
4.308 
 
.447 
   
   
   
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meals 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Linear 
Meals 
Quadratic 
 
 
Linear 
Error(Meals) 
Quadratic 
 
6234.722 
 
1 
 
6234.722 
 
2.367 
 
.163 
 
10168.167 
 
 
21074.778 
 
1 
 
 
8 
 
10168.167 
 
 
2634.347 
 
8.670 
 
.019 
 
9382.333 
 
8 
 
1172.792   
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Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meals 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Linear 
Meals 
Quadratic 
 
 
Linear 
Error(Meals) 
Quadratic 
 
.228 
 
2.367 
 
.274 
 
.520 
 
8.670 
 
.732 
   
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Intercept 
 
 
Error 
 
598533.333 
 
 
139616.667 
 
1 
 
 
8 
 
598533.333 
 
 
17452.083 
 
34.296 
 
.000 
 
.811 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Noncent. Parameter 
 
Observed Power 
 
Intercept 
 
 
Error 
 
34.296 
 
.999 
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a. Computed using alpha = .05 
 
Estimated Marginal Means 
 
Meals 
 
 
Estimates 
 
 
Measure:   MEASURE_1 
 
 
Meals 
 
Mean 
 
Std. Error 
 
95% Confidence Interval 
 
Lower Bound 
 
Upper Bound 
 
1 
 
 
2 
 
 
3 
 
116.556 
 
 
176.333 
 
 
153.778 
 
23.406 
 
 
29.922 
 
 
30.314 
 
62.581 
 
 
107.333 
 
 
83.873 
 
170.530 
 
 
245.334 
 
 
223.683 
 
 
 
Pairwise Comparisons 
 
Measure:   MEASURE_1 
 
 
(I) Meals (J) Meals 
 
Mean Difference 
 
(I-J) 
 
Std. Error Sig.
b
 
 
95% Confidence Interval for 
Difference
b
 
 
Lower Bound 
 
Upper Bound 
 
2 
1 
3 
 
 
1 
2 
3 
 
 
1 
3 
2 
-59.778
*
 
 
10.326 
 
.000 
 
-83.590 
 
-35.965 
 
-37.222 
 
59.778
*
 
 
 
22.556 
 
 
37.222 
 
24.195 
 
 
10.326 
 
 
24.021 
 
 
24.195 
 
.163 
 
 
.000 
 
 
.375 
 
 
.163 
 
-93.017 
 
 
35.965 
 
 
-32.837 
 
 
-18.572 
 
18.572 
 
 
83.590 
 
 
77.948 
 
 
93.017 
 
-22.556 
 
24.021 
 
.375 
 
-77.948 
 
32.837 
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Based on estimated marginal means 
 
 
*. The mean difference is significant at the .05 level. 
 
 
b. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
 
 
 
 
 
Multivariate Tests 
 
 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
.807 
 
 
.193 
 
 
4.194 
 
 
4.194 
14.681
a
 
 
14.681
a
 
 
14.681
a
 
 
14.681
a
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
7.000 
 
 
7.000 
 
 
7.000 
 
 
7.000 
 
.003 
 
 
.003 
 
 
.003 
 
 
.003 
 
.807 
 
 
.807 
 
 
.807 
 
 
.807 
 
 
 
Multivariate Tests 
 
 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
29.361 
 
 
29.361 
 
 
29.361 
 
 
29.361 
.975
a
 
 
.975
a
 
 
.975
a
 
 
.975
a
 
 
 
 
Each F tests the multivariate effect of Meals. These tests are based on the linearly independent pairwise 
comparisons among the estimated marginal means. 
 
a. Exact statistic 
 
 
b. Computed using alpha = .05 
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GLM TG_25_4 TG_50_4 TG_75_4 
 
/WSFACTOR=Meals 3 Polynomial 
 
/METHOD=SSTYPE(3) 
 
/EMMEANS=TABLES(Meals) COMPARE ADJ(LSD) 
 
/PRINT=DESCRIPTIVE ETASQ OPOWER 
 
/CRITERIA=ALPHA(.05) 
 
/WSDESIGN=Meals. 
 
General Linear Model- one-way repeated measures ANOVA for TG at 4 hrs 
[DataSet3] E:\Documents\Thesis (Lipid Load)\SPSS\TG Data.sav 
 
 
Within-Subjects Factors 
 
 
Measure:   MEASURE_1 
 
 
Meals 
 
Dependent 
 
Variable 
 
1 
 
 
2 
 
 
3 
 
TG_25_4 
 
 
TG_50_4 
 
 
TG_75_4 
 
 
 
Descriptive Statistics 
 
 
 
Mean 
 
Std. Deviation 
 
N 
 
TG_25_4 
 
 
TG_50_4 
 
 
TG_75_4 
 
73.50 
 
 
111.12 
 
 
144.00 
 
32.183 
 
 
83.762 
 
 
106.957 
 
8 
 
 
8 
 
 
8 
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Multivariate Tests
a
 
 
 
Effect 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meals 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.435 2.308
b
 
 
2.000 
 
6.000 
 
.180 
 
.565 2.308
b
 
 
2.000 
 
6.000 
 
.180 
 
.769 2.308
b
 
 
2.000 
 
6.000 
 
.180 
 
.769 2.308
b
 
 
2.000 
 
6.000 
 
.180 
 
 
Multivariate Tests
a
 
 
 
Effect 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meals 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.435 4.617
b
 
 
.303 
 
.435 4.617
b
 
 
.303 
 
.435 4.617
b
 
 
.303 
 
.435 4.617
b
 
 
.303 
 
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meals 
b. Exact statistic 
c. Computed using alpha = .05 
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Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Mauchly's W 
 
Approx. Chi- 
Square 
 
df 
 
Sig. Epsilon
b
 
 
Greenhouse- 
Geisser 
 
Meals 
 
.536 
 
3.742 
 
2 
 
.154 
 
.683 
 
 
Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Epsilon 
 
Huynh-Feldt 
 
Lower-bound 
 
Meals 
 
.792 
 
.500 
 
 
 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix.
a
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meals 
 
 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are 
displayed in the Tests of Within-Subjects Effects table. 
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Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Meals 
Huynh-Feldt 
 
 
Lower-bound 
 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Error(Meals) 
Huynh-Feldt 
 
 
Lower-bound 
 
19911.083 
 
2 
 
9955.542 
 
4.189 
 
.038 
 
19911.083 
 
1.366 
 
14575.422 
 
4.189 
 
.060 
 
19911.083 
 
1.585 
 
12563.879 
 
4.189 
 
.051 
 
19911.083 
 
 
33272.250 
 
1.000 
 
 
14 
 
19911.083 
 
 
2376.589 
 
4.189 
 
.080 
 
33272.250 
 
9.563 
 
3479.448   
 
33272.250 
 
11.094 
 
2999.252   
 
33272.250 
 
7.000 
 
4753.179   
 
 
 
Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Partial Eta Squared 
 
Noncent. 
Parameter 
 
Observed Power 
 
 
 
 
 
Meals 
 
 
 
 
 
 
 
 
 
Error(Meals) 
 
Sphericity Assumed 
Greenhouse-Geisser 
Huynh-Feldt 
Lower-bound 
Sphericity Assumed 
Greenhouse-Geisser 
Huynh-Feldt 
 
.374 
 
8.378 
 
.637 
 
.374 
 
5.722 
 
.511 
 
.374 
 
6.639 
 
.558 
 
.374 
 
4.189 
 
.424 
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Lower-bound 
 
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meals 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Linear 
Meals 
Quadratic 
 
 
Linear 
Error(Meals) 
Quadratic 
 
19881.000 
 
1 
 
19881.000 
 
5.104 
 
.058 
 
30.083 
 
 
27267.000 
 
1 
 
 
7 
 
30.083 
 
 
3895.286 
 
.035 
 
.857 
 
6005.250 
 
7 
 
857.893   
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meals 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Linear 
Meals 
Quadratic 
 
 
Linear 
Error(Meals) 
Quadratic 
 
.422 
 
5.104 
 
.495 
 
.005 
 
.035 
 
.053 
   
 
 
 
a. Computed using alpha = .05 
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Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Intercept 
 
 
Error 
 
287985.042 
 
 
103168.625 
 
1 
 
 
7 
 
287985.042 
 
 
14738.375 
 
19.540 
 
.003 
 
.736 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Noncent. Parameter 
 
Observed Power 
 
Intercept 
 
 
Error 
 
19.540 
 
.964 
 
 
 
a. Computed using alpha = .05 
 
Estimated Marginal Means 
 
Meals 
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Multivariate Tests 
 
 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
.435 
 
 
.565 
 
 
.769 
 
 
.769 
2.308
a
 
 
2.308
a
 
 
2.308
a
 
 
2.308
a
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
6.000 
 
 
6.000 
 
 
6.000 
 
 
6.000 
 
.180 
 
 
.180 
 
 
.180 
 
 
.180 
 
.435 
 
 
.435 
 
 
.435 
 
 
.435 
 
 
 
Multivariate Tests 
 
 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
4.617 
 
 
4.617 
 
 
4.617 
 
 
4.617 
.303
a
 
 
.303
a
 
 
.303
a
 
 
.303
a
 
 
 
 
Each F tests the multivariate effect of Meals. These tests are based on the linearly independent pairwise 
comparisons among the estimated marginal means. 
 
a. Exact statistic 
 
 
b. Computed using alpha = .05 
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Estimates 
 
Measure:   MEASURE_1 
 
 
Meals 
 
Mean 
 
Std. Error 
 
95% Confidence Interval 
 
Lower Bound 
 
Upper Bound 
 
1 
 
 
2 
 
 
3 
 
73.500 
 
 
111.125 
 
 
144.000 
 
11.378 
 
 
29.614 
 
 
37.815 
 
46.595 
 
 
41.098 
 
 
54.582 
 
100.405 
 
 
181.152 
 
 
233.418 
 
 
 
Pairwise Comparisons 
 
Measure:   MEASURE_1 
 
 
(I) Meals (J) Meals 
 
Mean Difference 
 
(I-J) 
 
Std. Error Sig.
a
 
 
95% Confidence Interval for 
Difference
a
 
 
Lower Bound 
 
Upper Bound 
 
2 
1 
3 
 
 
1 
2 
3 
 
 
1 
3 
2 
 
-37.625 
 
22.929 
 
.145 
 
-91.844 
 
16.594 
 
-70.500 
 
 
37.625 
 
 
-32.875 
 
 
70.500 
 
31.206 
 
 
22.929 
 
 
16.819 
 
 
31.206 
 
.058 
 
 
.145 
 
 
.092 
 
 
.058 
 
-144.291 
 
 
-16.594 
 
 
-72.645 
 
 
-3.291 
 
3.291 
 
 
91.844 
 
 
6.895 
 
 
144.291 
 
32.875 
 
16.819 
 
.092 
 
-6.895 
 
72.645 
 
 
 
Based on estimated marginal means 
 
 
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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T-TEST PAIRS=TG_25 TG_25 TG_50 WITH TG_50 TG_75 TG_75 (PAIRED) 
 
/CRITERIA=CI(.9500) 
 
/MISSING=ANALYSIS. 
 
t-Test for TG 
 
[DataSet3] E:\Documents\Thesis (Lipid Load)\SPSS\TG Data.sav 
 
 
Paired Samples Statistics 
 
 
 
Mean 
 
N 
 
Std. Deviation 
 
Std. Error Mean 
 
TG_25 
Pair 1 
TG_50 
 
 
TG_25 
Pair 2 
TG_75 
 
 
TG_50 
Pair 3 
TG_75 
 
98.00 
 
29 
 
70.255 
 
13.046 
 
142.14 
 
 
90.38 
 
 
113.73 
 
 
126.22 
 
29 
 
 
26 
 
 
26 
 
 
27 
 
117.904 
 
 
63.959 
 
 
89.043 
 
 
97.896 
 
21.894 
 
 
12.543 
 
 
17.463 
 
 
18.840 
 
117.59 
 
27 
 
89.590 
 
17.242 
 
 
 
Paired Samples Correlations 
 
 
 
N 
 
Correlation 
 
Sig. 
 
Pair 1 TG_25 & TG_50 
 
 
Pair 2 TG_25 & TG_75 
 
 
Pair 3 TG_50 & TG_75 
 
29 
 
 
26 
 
 
27 
 
.888 
 
 
.032 
 
 
.068 
 
.000 
 
 
.875 
 
 
.737 
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Paired Samples Test 
 
 
 
Paired Differences 
 
Mean 
 
Std. Deviation 
 
Std. Error Mean 
 
95% Confidence Interval of the 
 
Difference 
 
Lower 
 
Upper 
 
Pair 1 TG_25 - TG_50 
 
 
Pair 2 TG_25 - TG_75 
 
 
Pair 3 TG_50 - TG_75 
 
-44.138 
 
 
-23.346 
 
 
8.630 
 
64.201 
 
 
107.934 
 
 
128.139 
 
11.922 
 
 
21.168 
 
 
24.660 
 
-68.559 
 
 
-66.942 
 
 
-42.061 
 
-19.717 
 
 
20.249 
 
 
59.320 
 
 
 
Paired Samples Test 
 
 
 
t 
 
df 
 
Sig. (2-tailed) 
 
Pair 1 TG_25 - TG_50 
 
 
Pair 2 TG_25 - TG_75 
 
 
Pair 3 TG_50 - TG_75 
 
-3.702 
 
 
-1.103 
 
 
.350 
 
28 
 
 
25 
 
 
26 
 
.001 
 
 
.281 
 
 
.729 
 
 
 
GLM TBARS_25_B TBARS_50_B TBARS_75_B 
 
/WSFACTOR=Meal 3 Polynomial 
 
/METHOD=SSTYPE(3) 
 
/EMMEANS=TABLES(Meal) COMPARE ADJ(LSD) 
 
/PRINT=DESCRIPTIVE ETASQ OPOWER 
 
/CRITERIA=ALPHA(.05) 
 
/WSDESIGN=Meal. 
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General Linear Model- one-way repeated measures ANOVA for TBARS at 
baseline 
[DataSet2] H:\Documents\Thesis (Lipid Load)\SPSS\TBARS Data.sav 
 
 
Within-Subjects Factors 
 
 
Measure:   MEASURE_1 
 
 
Meal 
 
Dependent 
 
Variable 
 
1 
 
 
2 
 
 
3 
 
TBARS_25_B 
TBARS_50_B 
TBARS_75_B 
 
 
 
Descriptive Statistics 
 
 
 
Mean 
 
Std. Deviation 
 
N 
 
TBARS_25_B 
TBARS_50_B 
TBARS_75_B 
 
5.0556 
 
 
4.5667 
 
 
4.7889 
 
2.10601 
 
 
1.49164 
 
 
1.34019 
 
9 
 
 
9 
 
 
9 
 
 
 
Multivariate Tests
a
 
 
 
Effect 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meal 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.091 .350
b
 
 
2.000 
 
7.000 
 
.716 
 
.909 .350
b
 
 
2.000 
 
7.000 
 
.716 
 
.100 .350
b
 
 
2.000 
 
7.000 
 
.716 
 
.100 .350
b
 
 
2.000 
 
7.000 
 
.716 
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Multivariate Tests
a
 
 
 
Effect 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meal 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.091 .701
b
 
 
.087 
 
.091 .701
b
 
 
.087 
 
.091 .701
b
 
 
.087 
 
.091 .701
b
 
 
.087 
 
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meal 
b. Exact statistic 
c. Computed using alpha = .05 
 
 
 
 
Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Mauchly's W 
 
Approx. Chi- 
Square 
 
df 
 
Sig. Epsilon
b
 
 
Greenhouse- 
Geisser 
 
Meal 
 
.720 
 
2.304 
 
2 
 
.316 
 
.781 
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Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Epsilon 
 
Huynh-Feldt 
 
Lower-bound 
 
Meal 
 
.936 
 
.500 
 
 
 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix.
a
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meal 
 
 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are 
displayed in the Tests of Within-Subjects Effects table. 
 
 
 
 
Tests of Within-Subjects Effects 
 
 
Measure:   MEASURE_1 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Meal 
Huynh-Feldt 
 
 
Lower-bound 
 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Error(Meal) 
Huynh-Feldt 
 
 
Lower-bound 
 
1.079 
 
2 
 
.539 
 
.203 
 
.819 
 
1.079 
 
1.562 
 
.690 
 
.203 
 
.766 
 
1.079 
 
1.873 
 
.576 
 
.203 
 
.805 
 
1.079 
 
 
42.581 
 
1.000 
 
 
16 
 
1.079 
 
 
2.661 
 
.203 
 
.665 
 
42.581 
 
12.496 
 
3.408   
 
42.581 
 
14.983 
 
2.842   
 
42.581 
 
8.000 
 
5.323   
110  
 
 
 
Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Meal 
Huynh-Feldt Lower-
bound Sphericity 
Assumed 
Greenhouse-Geisser 
Error(Meal) 
Huynh-Feldt 
 
 
Lower-bound 
 
.025 
 
.405 
 
.076 
 
.025 
 
.316 
 
.073 
 
.025 
 
.379 
 
.075 
 
.025 
 
.203 
 
.068 
   
   
   
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meal 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Linear 
Meal 
Quadratic 
 
 
Linear 
Error(Meal) 
Quadratic 
 
.320 
 
1 
 
.320 
 
.082 
 
.782 
 
.759 
 
 
31.160 
 
1 
 
 
8 
 
.759 
 
 
3.895 
 
.531 
 
.487 
 
11.421 
 
8 
 
1.428   
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Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meal 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Linear 
Meal 
Quadratic 
 
 
Linear 
Error(Meal) 
Quadratic 
 
.010 
 
.082 
 
.057 
 
.062 
 
.531 
 
.099 
   
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Intercept 
 
 
Error 
 
623.040 
 
 
25.070 
 
1 
 
 
8 
 
623.040 
 
 
3.134 
 
198.819 
 
.000 
 
.961 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Noncent. Parameter 
 
Observed Power 
 
Intercept 
 
 
Error 
 
198.819 
 
1.000 
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a. Computed using alpha = .05 
 
 
 
 
Estimated Marginal Means 
 
Meal 
 
 
Estimates 
 
 
Measure:   MEASURE_1 
 
 
Meal 
 
Mean 
 
Std. Error 
 
95% Confidence Interval 
 
Lower Bound 
 
Upper Bound 
 
1 
 
 
2 
 
 
3 
 
5.056 
 
 
4.567 
 
 
4.789 
 
.702 
 
 
.497 
 
 
.447 
 
3.437 
 
 
3.420 
 
 
3.759 
 
6.674 
 
 
5.713 
 
 
5.819 
 
 
 
Pairwise Comparisons 
 
Measure:   MEASURE_1 
 
 
(I) Meal (J) Meal 
 
Mean Difference 
 
(I-J) 
 
Std. Error Sig.
a
 
 
95% Confidence Interval for 
Difference
a
 
 
Lower Bound 
 
Upper Bound 
 
2 
1 
3 
 
 
1 
2 
3 
 
 
1 
3 
2 
 
.489 
 
.568 
 
.415 
 
-.822 
 
1.800 
 
.267 
 
 
-.489 
 
 
-.222 
 
 
-.267 
 
.930 
 
 
.568 
 
 
.765 
 
 
.930 
 
.782 
 
 
.415 
 
 
.779 
 
 
.782 
 
-1.879 
 
 
-1.800 
 
 
-1.987 
 
 
-2.412 
 
2.412 
 
 
.822 
 
 
1.542 
 
 
1.879 
 
.222 
 
.765 
 
.779 
 
-1.542 
 
1.987 
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Based on estimated marginal means 
 
 
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
 
 
 
 
 
Multivariate Tests 
 
 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
.091 
 
 
.909 
 
 
.100 
 
 
.100 
.350
a
 
 
.350
a
 
 
.350
a
 
 
.350
a
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
7.000 
 
 
7.000 
 
 
7.000 
 
 
7.000 
 
.716 
 
 
.716 
 
 
.716 
 
 
.716 
 
.091 
 
 
.091 
 
 
.091 
 
 
.091 
 
 
 
Multivariate Tests 
 
 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
.701 
 
 
.701 
 
 
.701 
 
 
.701 
.087
a
 
 
.087
a
 
 
.087
a
 
 
.087
a
 
 
 
 
Each F tests the multivariate effect of Meal. These tests are based on the linearly independent pairwise 
comparisons among the estimated marginal means. 
 
a. Exact statistic 
 
 
b. Computed using alpha = .05 
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GLM TBARS_25_2 TBARS_50_2 TBARS_75_2 
 
/WSFACTOR=Meal 3 Polynomial 
 
/METHOD=SSTYPE(3) 
 
/EMMEANS=TABLES(Meal) COMPARE ADJ(LSD) 
 
/PRINT=DESCRIPTIVE ETASQ OPOWER 
 
/CRITERIA=ALPHA(.05) 
 
/WSDESIGN=Meal. 
 
General Linear Model- one-way repeated measures ANOVA for TBARS at 2 
hrs 
[DataSet2] H:\Documents\Thesis (Lipid Load)\SPSS\TBARS Data.sav 
 
 
Within-Subjects Factors 
 
 
Measure:   MEASURE_1 
 
 
Meal 
 
Dependent 
 
Variable 
 
1 
 
 
2 
 
 
3 
 
TBARS_25_2 
 
 
TBARS_50_2 
 
 
TBARS_75_2 
 
 
 
Descriptive Statistics 
 
 
 
Mean 
 
Std. Deviation 
 
N 
 
TBARS_25_2 
 
 
TBARS_50_2 
 
 
TBARS_75_2 
 
5.4333 
 
 
4.2444 
 
 
4.3111 
 
1.94551 
 
 
1.27976 
 
 
1.21186 
 
9 
 
 
9 
 
 
9 
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Multivariate Tests
a
 
 
 
Effect 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meal 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.185 .795
b
 
 
2.000 
 
7.000 
 
.488 
 
.815 .795
b
 
 
2.000 
 
7.000 
 
.488 
 
.227 .795
b
 
 
2.000 
 
7.000 
 
.488 
 
.227 .795
b
 
 
2.000 
 
7.000 
 
.488 
 
 
Multivariate Tests
a
 
 
 
Effect 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meal 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.185 1.590
b
 
 
.138 
 
.185 1.590
b
 
 
.138 
 
.185 1.590
b
 
 
.138 
 
.185 1.590
b
 
 
.138 
 
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meal 
b. Exact statistic 
c. Computed using alpha = .05 
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Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Mauchly's W 
 
Approx. Chi- 
Square 
 
df 
 
Sig. Epsilon
b
 
 
Greenhouse- 
Geisser 
 
Meal 
 
.201 
 
11.218 
 
2 
 
.004 
 
.556 
 
 
Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Epsilon 
 
Huynh-Feldt 
 
Lower-bound 
 
Meal 
 
.581 
 
.500 
 
 
 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix.
a
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meal 
 
 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are 
displayed in the Tests of Within-Subjects Effects table. 
117  
Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Meal 
Huynh-Feldt 
 
 
Lower-bound 
 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Error(Meal) 
Huynh-Feldt 
 
 
Lower-bound 
 
8.032 
 
2 
 
4.016 
 
1.712 
 
.212 
 
8.032 
 
1.112 
 
7.223 
 
1.712 
 
.226 
 
8.032 
 
1.163 
 
6.909 
 
1.712 
 
.226 
 
8.032 
 
 
37.541 
 
1.000 
 
 
16 
 
8.032 
 
 
2.346 
 
1.712 
 
.227 
 
37.541 
 
8.896 
 
4.220   
 
37.541 
 
9.300 
 
4.037   
 
37.541 
 
8.000 
 
4.693   
 
 
 
Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
 
 
 
 
Meal 
 
 
 
 
 
 
 
 
 
Error(Meal) 
 
Sphericity Assumed 
Greenhouse-Geisser 
Huynh-Feldt 
Lower-bound 
 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
 
 
Huynh-Feldt 
 
.176 
 
3.423 
 
.306 
 
.176 
 
1.903 
 
.223 
 
.176 
 
1.990 
 
.228 
 
.176 
 
1.712 
 
.211 
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Lower-bound 
 
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meal 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Linear 
Meal 
Quadratic 
 
 
Linear 
Error(Meal) 
Quadratic 
 
5.667 
 
1 
 
5.667 
 
1.805 
 
.216 
 
2.365 
 
 
25.118 
 
1 
 
 
8 
 
2.365 
 
 
3.140 
 
1.523 
 
.252 
 
12.424 
 
8 
 
1.553   
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meal 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Linear 
Meal 
Quadratic 
 
 
Linear 
Error(Meal) 
Quadratic 
 
.184 
 
1.805 
 
.220 
 
.160 
 
1.523 
 
.193 
   
 
 
 
a. Computed using alpha = .05 
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Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Intercept 
 
 
Error 
 
587.067 
 
 
17.590 
 
1 
 
 
8 
 
587.067 
 
 
2.199 
 
267.006 
 
.000 
 
.971 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Noncent. Parameter 
 
Observed Power 
 
Intercept 
 
 
Error 
 
267.006 
 
1.000 
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Estimated Marginal Means 
 
Meal 
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Estimates 
 
Measure:   MEASURE_1 
 
 
Meal 
 
Mean 
 
Std. Error 
 
95% Confidence Interval 
 
Lower Bound 
 
Upper Bound 
 
1 
 
 
2 
 
 
3 
 
5.433 
 
 
4.244 
 
 
4.311 
 
.649 
 
 
.427 
 
 
.404 
 
3.938 
 
 
3.261 
 
 
3.380 
 
6.929 
 
 
5.228 
 
 
5.243 
 
 
 
Pairwise Comparisons 
 
Measure:   MEASURE_1 
 
 
(I) Meal (J) Meal 
 
Mean Difference 
 
(I-J) 
 
Std. Error Sig.
a
 
 
95% Confidence Interval for 
Difference
a
 
 
Lower Bound 
 
Upper Bound 
 
2 
1 
3 
 
 
1 
2 
3 
 
 
1 
3 
2 
 
1.189 
 
.898 
 
.222 
 
-.882 
 
3.260 
 
1.122 
 
 
-1.189 
 
 
-.067 
 
 
-1.122 
 
.835 
 
 
.898 
 
 
.244 
 
 
.835 
 
.216 
 
 
.222 
 
 
.792 
 
 
.216 
 
-.804 
 
 
-3.260 
 
 
-.630 
 
 
-3.048 
 
3.048 
 
 
.882 
 
 
.497 
 
 
.804 
 
.067 
 
.244 
 
.792 
 
-.497 
 
.630 
 
 
 
Based on estimated marginal means 
 
 
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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Multivariate Tests 
 
 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
.185 
 
 
.815 
 
 
.227 
 
 
.227 
.795
a
 
 
.795
a
 
 
.795
a
 
 
.795
a
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
7.000 
 
 
7.000 
 
 
7.000 
 
 
7.000 
 
.488 
 
 
.488 
 
 
.488 
 
 
.488 
 
.185 
 
 
.185 
 
 
.185 
 
 
.185 
 
 
 
Multivariate Tests 
 
 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
1.590 
 
 
1.590 
 
 
1.590 
 
 
1.590 
.138
a
 
 
.138
a
 
 
.138
a
 
 
.138
a
 
 
 
 
Each F tests the multivariate effect of Meal. These tests are based on the linearly independent pairwise 
comparisons among the estimated marginal means. 
 
a. Exact statistic 
 
 
b. Computed using alpha = .05 
 
 
 
 
GLM TBARS_25_4 TBARS_50_4 TBARS_75_4 
 
/WSFACTOR=Meal 3 Polynomial 
 
/METHOD=SSTYPE(3) 
 
/EMMEANS=TABLES(Meal) COMPARE ADJ(LSD) 
 
/PRINT=DESCRIPTIVE ETASQ OPOWER 
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/CRITERIA=ALPHA(.05) 
 
/WSDESIGN=Meal. 
 
General Linear Model- one-way repeated measures ANOVA for TBARS at 4 
hrs 
 
[DataSet2] H:\Documents\Thesis (Lipid Load)\SPSS\TBARS Data.sav 
 
 
Within-Subjects Factors 
 
 
Measure:   MEASURE_1 
 
 
Meal 
 
Dependent 
 
Variable 
 
1 
 
 
2 
 
 
3 
 
TBARS_25_4 
 
 
TBARS_50_4 
 
 
TBARS_75_4 
 
 
 
Descriptive Statistics 
 
 
 
Mean 
 
Std. Deviation 
 
N 
 
TBARS_25_4 
 
 
TBARS_50_4 
 
 
TBARS_75_4 
 
4.0875 
 
 
4.2875 
 
 
4.8750 
 
1.21941 
 
 
.87413 
 
 
1.75153 
 
8 
 
 
8 
 
 
8 
 
 
 
Multivariate Tests
a
 
 
 
Effect 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
 
 
Meal 
 
Pillai's Trace 
 
 
Wilks' Lambda 
 
 
Hotelling's Trace 
 
.190 .705
b
 
 
2.000 
 
6.000 
 
.531 
 
.810 .705
b
 
 
2.000 
 
6.000 
 
.531 
 
.235 .705
b
 
 
2.000 
 
6.000 
 
.531 
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Roy's Largest Root .235 .705
b 
2.000 6.000 .531 
 
 
 
 
Multivariate Tests
a
 
 
 
Effect 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meal 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.190 1.410
b
 
 
.122 
 
.190 1.410
b
 
 
.122 
 
.190 1.410
b
 
 
.122 
 
.190 1.410
b
 
 
.122 
 
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meal 
b. Exact statistic 
c. Computed using alpha = .05 
 
 
 
 
Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Mauchly's W 
 
Approx. Chi- 
Square 
 
df 
 
Sig. Epsilon
b
 
 
Greenhouse- 
Geisser 
 
Meal 
 
.543 
 
3.661 
 
2 
 
.160 
 
.686 
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Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Epsilon 
 
Huynh-Feldt 
 
Lower-bound 
 
Meal 
 
.798 
 
.500 
 
 
 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix.
a
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meal 
 
 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are 
displayed in the Tests of Within-Subjects Effects table. 
 
 
 
 
Tests of Within-Subjects Effects 
 
 
Measure:   MEASURE_1 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
 
 
 
 
Meal 
 
 
 
 
 
 
 
 
 
Error(Meal) 
 
Sphericity Assumed 
Greenhouse-Geisser 
Huynh-Feldt 
Lower-bound 
Sphericity Assumed 
Greenhouse-Geisser 
Huynh-Feldt 
 
2.681 
 
2 
 
1.340 
 
.728 
 
.500 
 
2.681 
 
1.373 
 
1.953 
 
.728 
 
.458 
 
2.681 
 
1.596 
 
1.679 
 
.728 
 
.475 
 
2.681 
 
 
25.766 
 
1.000 
 
 
14 
 
2.681 
 
 
1.840 
 
.728 
 
.422 
 
25.766 
 
9.610 
 
2.681   
 
25.766 
 
11.175 
 
2.306   
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Lower-bound 25.766 7.000 3.681 
 
 
 
 
Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Meal 
Huynh-Feldt Lower-
bound Sphericity 
Assumed 
Greenhouse-Geisser 
Error(Meal) 
Huynh-Feldt 
 
 
Lower-bound 
 
.094 
 
1.457 
 
.149 
 
.094 
 
1.000 
 
.129 
 
.094 
 
1.163 
 
.136 
 
.094 
 
.728 
 
.115 
   
   
   
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meal 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Linear 
Meal 
Quadratic 
 
 
Linear 
Error(Meal) 
Quadratic 
 
2.481 
 
1 
 
2.481 
 
.832 
 
.392 
 
.200 
 
 
20.874 
 
1 
 
 
7 
 
.200 
 
 
2.982 
 
.287 
 
.609 
 
4.891 
 
7 
 
.699   
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Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meal 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Linear 
Meal 
Quadratic 
 
 
Linear 
Error(Meal) 
Quadratic 
 
.106 
 
.832 
 
.124 
 
.039 
 
.287 
 
.075 
   
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Intercept 
 
 
Error 
 
468.167 
 
 
11.467 
 
1 
 
 
7 
 
468.167 
 
 
1.638 
 
285.799 
 
.000 
 
.976 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Noncent. Parameter 
 
Observed Power 
 
Intercept 
 
285.799 
 
1.000 
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Error 
 
 
 
 
a. Computed using alpha = .05 
 
Estimated Marginal Means 
 
Meal 
 
 
Estimates 
 
 
Measure:   MEASURE_1 
 
 
Meal 
 
Mean 
 
Std. Error 
 
95% Confidence Interval 
 
Lower Bound 
 
Upper Bound 
 
1 
 
 
2 
 
 
3 
 
4.088 
 
 
4.288 
 
 
4.875 
 
.431 
 
 
.309 
 
 
.619 
 
3.068 
 
 
3.557 
 
 
3.411 
 
5.107 
 
 
5.018 
 
 
6.339 
 
 
 
Pairwise Comparisons 
 
Measure:   MEASURE_1 
 
 
(I) Meal (J) Meal 
 
Mean Difference 
 
(I-J) 
 
Std. Error Sig.
a
 
 
95% Confidence Interval for 
Difference
a
 
 
Lower Bound 
 
Upper Bound 
 
2 
1 
3 
 
 
1 
2 
3 
 
 
1 
3 
2 
 
-.200 
 
.651 
 
.768 
 
-1.740 
 
1.340 
 
-.787 
 
 
.200 
 
 
-.588 
 
 
.787 
 
.863 
 
 
.651 
 
 
.459 
 
 
.863 
 
.392 
 
 
.768 
 
 
.241 
 
 
.392 
 
-2.829 
 
 
-1.340 
 
 
-1.672 
 
 
-1.254 
 
1.254 
 
 
1.740 
 
 
.497 
 
 
2.829 
 
.588 
 
.459 
 
.241 
 
-.497 
 
1.672 
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Based on estimated marginal means 
 
 
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
 
 
 
 
 
Multivariate Tests 
 
 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
.190 
 
 
.810 
 
 
.235 
 
 
.235 
.705
a
 
 
.705
a
 
 
.705
a
 
 
.705
a
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
6.000 
 
 
6.000 
 
 
6.000 
 
 
6.000 
 
.531 
 
 
.531 
 
 
.531 
 
 
.531 
 
.190 
 
 
.190 
 
 
.190 
 
 
.190 
 
 
 
Multivariate Tests 
 
 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
1.410 
 
 
1.410 
 
 
1.410 
 
 
1.410 
.122
a
 
 
.122
a
 
 
.122
a
 
 
.122
a
 
 
 
 
Each F tests the multivariate effect of Meal. These tests are based on the linearly independent pairwise 
comparisons among the estimated marginal means. 
 
a. Exact statistic 
 
 
b. Computed using alpha = .05 
 
DATASET ACTIVATE DataSet2. 
DATASET CLOSE DataSet3. 
T-TEST PAIRS=TBARS_25 TBARS_25 TBARS_50 WITH TBARS_50 TBARS_75 TBARS_75 (PAIRED) 
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/CRITERIA=CI(.9500) 
 
/MISSING=ANALYSIS. 
 
t-Test for TBARS 
 
[DataSet2] H:\Documents\Thesis (Lipid Load)\SPSS\TBARS Data.sav 
 
 
Paired Samples Statistics 
 
 
 
Mean 
 
N 
 
Std. Deviation 
 
Std. Error Mean 
 
TBARS_25 
Pair 1 
TBARS_50 
 
 
TBARS_25 
Pair 2 
TBARS_75 
 
 
TBARS_50 
Pair 3 
TBARS_75 
 
5.0069 
 
29 
 
1.92297 
 
.35709 
 
4.6414 
 
 
4.9654 
 
 
4.6538 
 
 
4.6556 
 
29 
 
 
26 
 
 
26 
 
 
27 
 
1.59071 
 
 
2.00817 
 
 
1.40035 
 
 
1.63668 
 
.29539 
 
 
.39383 
 
 
.27463 
 
 
.31498 
 
4.6185 
 
27 
 
1.38537 
 
.26662 
 
 
 
Paired Samples Correlations 
 
 
 
N 
 
Correlation 
 
Sig. 
 
Pair 1 TBARS_25 & TBARS_50 
 
 
Pair 2 TBARS_25 & TBARS_75 
 
 
Pair 3 TBARS_50 & TBARS_75 
 
29 
 
 
26 
 
 
27 
 
.282 
 
 
.106 
 
 
.231 
 
.139 
 
 
.605 
 
 
.246 
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Paired Samples Test 
 
 
 
Paired Differences 
 
Mean 
 
Std. Deviation 
 
Std. Error Mean 
 
95% Confidence 
Interval of the 
Difference 
 
Lower 
 
Pair 1 TBARS_25 - TBARS_50 
 
 
Pair 2 TBARS_25 - TBARS_75 
 
 
Pair 3 TBARS_50 - TBARS_75 
 
.36552 
 
 
.31154 
 
 
.03704 
 
2.12254 
 
 
2.32281 
 
 
1.88397 
 
.39415 
 
 
.45554 
 
 
.36257 
 
-.44186 
 
 
-.62667 
 
 
-.70824 
 
 
 
Paired Samples Test 
 
 
 
Paired Differences 
 
t 
 
df 
 
Sig. (2-tailed) 
 
95% Confidence 
Interval of the 
Difference 
 
Upper 
 
Pair 1 TBARS_25 - TBARS_50 
 
 
Pair 2 TBARS_25 - TBARS_75 
 
 
Pair 3 TBARS_50 - TBARS_75 
 
1.17289 
 
 
1.24974 
 
 
.78231 
 
.927 
 
 
.684 
 
 
.102 
 
28 
 
 
25 
 
 
26 
 
.362 
 
 
.500 
 
 
.919 
 
 
 
GET 
 
FILE='E:\Documents\Thesis (Lipid Load)\SPSS\FMD Data.sav'. 
DATASET NAME DataSet1 WINDOW=FRONT. 
GLM FMD_25_B FMD_50_B FMD_75_B 
 
/WSFACTOR=Meal 3 Polynomial 
 
/METHOD=SSTYPE(3) 
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/EMMEANS=TABLES(Meal) COMPARE ADJ(LSD) 
 
/PRINT=DESCRIPTIVE ETASQ OPOWER 
 
/CRITERIA=ALPHA(.05) 
 
/WSDESIGN=Meal. 
 
General Linear Model- one-way repeated measures ANOVA for FMD at 
baseline 
 
[DataSet1] E:\Documents\Thesis (Lipid Load)\SPSS\FMD Data.sav 
 
 
Within-Subjects Factors 
 
 
Measure:   MEASURE_1 
 
 
Meal 
 
Dependent 
 
Variable 
 
1 
 
 
2 
 
 
3 
 
FMD_25_B 
FMD_50_B 
FMD_75_B 
 
 
 
Descriptive Statistics 
 
 
 
Mean 
 
Std. Deviation 
 
N 
 
FMD_25_B 
FMD_50_B 
FMD_75_B 
 
7.3310 
 
 
7.5950 
 
 
7.0110 
 
2.17961 
 
 
2.34750 
 
 
2.73309 
 
10 
 
 
10 
 
 
10 
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Multivariate Tests
a
 
 
 
Effect 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meal 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.084 .365
b
 
 
2.000 
 
8.000 
 
.705 
 
.916 .365
b
 
 
2.000 
 
8.000 
 
.705 
 
.091 .365
b
 
 
2.000 
 
8.000 
 
.705 
 
.091 .365
b
 
 
2.000 
 
8.000 
 
.705 
 
 
Multivariate Tests
a
 
 
 
Effect 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meal 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.084 .729
b
 
 
.090 
 
.084 .729
b
 
 
.090 
 
.084 .729
b
 
 
.090 
 
.084 .729
b
 
 
.090 
 
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meal 
b. Exact statistic 
c. Computed using alpha = .05 
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Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Mauchly's W 
 
Approx. Chi- 
Square 
 
df 
 
Sig. Epsilon
b
 
 
Greenhouse- 
Geisser 
 
Meal 
 
.973 
 
.217 
 
2 
 
.897 
 
.974 
 
 
Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Epsilon 
 
Huynh-Feldt 
 
Lower-bound 
 
Meal 
 
1.000 
 
.500 
 
 
 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix.
a
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meal 
 
 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are 
displayed in the Tests of Within-Subjects Effects table. 
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Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Meal 
Huynh-Feldt 
 
 
Lower-bound 
 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Error(Meal) 
Huynh-Feldt 
 
 
Lower-bound 
 
1.711 
 
2 
 
.855 
 
.344 
 
.713 
 
1.711 
 
1.948 
 
.878 
 
.344 
 
.708 
 
1.711 
 
2.000 
 
.855 
 
.344 
 
.713 
 
1.711 
 
 
44.704 
 
1.000 
 
 
18 
 
1.711 
 
 
2.484 
 
.344 
 
.572 
 
44.704 
 
17.530 
 
2.550   
 
44.704 
 
18.000 
 
2.484   
 
44.704 
 
9.000 
 
4.967   
 
 
 
Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
 
 
 
 
Meal 
 
 
 
 
 
 
 
Error(Meal) 
 
Sphericity Assumed 
Greenhouse-Geisser 
Huynh-Feldt 
Lower-bound 
 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
 
.037 
 
.689 
 
.097 
 
.037 
 
.671 
 
.096 
 
.037 
 
.689 
 
.097 
 
.037 
 
.344 
 
.082 
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Huynh-Feldt 
 
 
Lower-bound 
   
   
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meal 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Linear 
Meal 
Quadratic 
 
 
Linear 
Error(Meal) 
Quadratic 
 
.512 
 
1 
 
.512 
 
.188 
 
.675 
 
1.199 
 
 
24.525 
 
1 
 
 
9 
 
1.199 
 
 
2.725 
 
.535 
 
.483 
 
20.179 
 
9 
 
2.242   
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meal 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Linear 
Meal 
Quadratic 
 
 
Linear 
Error(Meal) 
Quadratic 
 
.020 
 
.188 
 
.068 
 
.056 
 
.535 
 
.101 
   
 
 
 
a. Computed using alpha = .05 
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Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Intercept 
 
 
Error 
 
1604.107 
 
 
114.877 
 
1 
 
 
9 
 
1604.107 
 
 
12.764 
 
125.673 
 
.000 
 
.933 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Noncent. Parameter 
 
Observed Power 
 
Intercept 
 
 
Error 
 
125.673 
 
1.000 
 
 
 
a. Computed using alpha = .05 
 
Estimated Marginal Means 
 
Meal 
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Estimates 
 
Measure:   MEASURE_1 
 
 
Meal 
 
Mean 
 
Std. Error 
 
95% Confidence Interval 
 
Lower Bound 
 
Upper Bound 
 
1 
 
 
2 
 
 
3 
 
7.331 
 
 
7.595 
 
 
7.011 
 
.689 
 
 
.742 
 
 
.864 
 
5.772 
 
 
5.916 
 
 
5.056 
 
8.890 
 
 
9.274 
 
 
8.966 
 
 
 
Pairwise Comparisons 
 
Measure:   MEASURE_1 
 
 
(I) Meal (J) Meal 
 
Mean Difference 
 
(I-J) 
 
Std. Error Sig.
a
 
 
95% Confidence Interval for 
Difference
a
 
 
Lower Bound 
 
Upper Bound 
 
2 
1 
3 
 
 
1 
2 
3 
 
 
1 
3 
2 
 
-.264 
 
.727 
 
.725 
 
-1.910 
 
1.382 
 
.320 
 
 
.264 
 
 
.584 
 
 
-.320 
 
.738 
 
 
.727 
 
 
.645 
 
 
.738 
 
.675 
 
 
.725 
 
 
.389 
 
 
.675 
 
-1.350 
 
 
-1.382 
 
 
-.875 
 
 
-1.990 
 
1.990 
 
 
1.910 
 
 
2.043 
 
 
1.350 
 
-.584 
 
.645 
 
.389 
 
-2.043 
 
.875 
 
 
 
Based on estimated marginal means 
 
 
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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Multivariate Tests 
 
 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
.084 
 
 
.916 
 
 
.091 
 
 
.091 
.365
a
 
 
.365
a
 
 
.365
a
 
 
.365
a
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
8.000 
 
 
8.000 
 
 
8.000 
 
 
8.000 
 
.705 
 
 
.705 
 
 
.705 
 
 
.705 
 
.084 
 
 
.084 
 
 
.084 
 
 
.084 
 
 
 
Multivariate Tests 
 
 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
.729 
 
 
.729 
 
 
.729 
 
 
.729 
.090
a
 
 
.090
a
 
 
.090
a
 
 
.090
a
 
 
 
 
Each F tests the multivariate effect of Meal. These tests are based on the linearly independent pairwise 
comparisons among the estimated marginal means. 
 
a. Exact statistic 
 
 
b. Computed using alpha = .05 
 
 
 
 
GLM FMD_25_2 FMD_50_2 FMD_75_2 
 
/WSFACTOR=Meal 3 Polynomial 
 
/METHOD=SSTYPE(3) 
 
/EMMEANS=TABLES(Meal) COMPARE ADJ(LSD) 
139  
/PRINT=DESCRIPTIVE ETASQ OPOWER 
 
/CRITERIA=ALPHA(.05) 
 
/WSDESIGN=Meal. 
 
General Linear Model- one-way repeated measures ANOVA for FMD at 2 hrs 
 
[DataSet1] E:\Documents\Thesis (Lipid Load)\SPSS\FMD Data.sav 
 
 
Within-Subjects Factors 
 
 
Measure:   MEASURE_1 
 
 
Meal 
 
Dependent 
 
Variable 
 
1 
 
 
2 
 
 
3 
 
FMD_25_2 
 
 
FMD_50_2 
 
 
FMD_75_2 
 
 
 
Descriptive Statistics 
 
 
 
Mean 
 
Std. Deviation 
 
N 
 
FMD_25_2 
 
 
FMD_50_2 
 
 
FMD_75_2 
 
7.1130 
 
 
5.8700 
 
 
5.4430 
 
2.74991 
 
 
2.00694 
 
 
2.89440 
 
10 
 
 
10 
 
 
10 
 
 
 
Multivariate Tests
a
 
 
 
Effect 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
 
 
Meal 
 
Pillai's Trace 
 
 
Wilks' Lambda 
 
 
Hotelling's Trace 
 
.635 6.968
b
 
 
2.000 
 
8.000 
 
.018 
 
.365 6.968
b
 
 
2.000 
 
8.000 
 
.018 
 
1.742 6.968
b
 
 
2.000 
 
8.000 
 
.018 
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Roy's Largest Root 1.742 6.968
b 
2.000 8.000 .018 
 
 
 
 
Multivariate Tests
a
 
 
 
Effect 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meal 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.635 13.936
b
 
 
.788 
 
.635 13.936
b
 
 
.788 
 
.635 13.936
b
 
 
.788 
 
.635 13.936
b
 
 
.788 
 
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meal 
b. Exact statistic 
c. Computed using alpha = .05 
 
 
 
 
Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Mauchly's W 
 
Approx. Chi- 
Square 
 
df 
 
Sig. Epsilon
b
 
 
Greenhouse- 
Geisser 
 
Meal 
 
.498 
 
5.571 
 
2 
 
.062 
 
.666 
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Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Epsilon 
 
Huynh-Feldt 
 
Lower-bound 
 
Meal 
 
.738 
 
.500 
 
 
 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix.
a
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meal 
 
 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are 
displayed in the Tests of Within-Subjects Effects table. 
 
 
 
 
Tests of Within-Subjects Effects 
 
 
Measure:   MEASURE_1 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
 
 
 
 
Meal 
 
 
 
 
 
 
 
 
 
Error(Meal) 
 
Sphericity Assumed 
Greenhouse-Geisser 
Huynh-Feldt 
Lower-bound 
Sphericity Assumed 
Greenhouse-Geisser 
Huynh-Feldt 
 
15.054 
 
2 
 
7.527 
 
2.402 
 
.119 
 
15.054 
 
1.332 
 
11.303 
 
2.402 
 
.143 
 
15.054 
 
1.476 
 
10.199 
 
2.402 
 
.138 
 
15.054 
 
 
56.418 
 
1.000 
 
 
18 
 
15.054 
 
 
3.134 
 
2.402 
 
.156 
 
56.418 
 
11.987 
 
4.707   
 
56.418 
 
13.285 
 
4.247   
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Lower-bound 56.418 9.000 6.269 
 
 
 
 
Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Meal 
Huynh-Feldt Lower-
bound Sphericity 
Assumed 
Greenhouse-Geisser 
Error(Meal) 
Huynh-Feldt 
 
 
Lower-bound 
 
.211 
 
4.803 
 
.421 
 
.211 
 
3.199 
 
.332 
 
.211 
 
3.545 
 
.352 
 
.211 
 
2.402 
 
.284 
   
   
   
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meal 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Linear 
Meal 
Quadratic 
 
 
Linear 
Error(Meal) 
Quadratic 
 
13.945 
 
1 
 
13.945 
 
6.973 
 
.027 
 
1.110 
 
 
17.997 
 
1 
 
 
9 
 
1.110 
 
 
2.000 
 
.260 
 
.622 
 
38.420 
 
9 
 
4.269   
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Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meal 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Linear 
Meal 
Quadratic 
 
 
Linear 
Error(Meal) 
Quadratic 
 
.437 
 
6.973 
 
.653 
 
.028 
 
.260 
 
.074 
   
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Intercept 
 
 
Error 
 
1131.725 
 
 
123.289 
 
1 
 
 
9 
 
1131.725 
 
 
13.699 
 
82.615 
 
.000 
 
.902 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Noncent. Parameter 
 
Observed Power 
 
Intercept 
 
82.615 
 
1.000 
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Error 
 
 
 
 
a. Computed using alpha = .05 
 
Estimated Marginal Means 
 
Meal 
 
 
Estimates 
 
 
Measure:   MEASURE_1 
 
 
Meal 
 
Mean 
 
Std. Error 
 
95% Confidence Interval 
 
Lower Bound 
 
Upper Bound 
 
1 
 
 
2 
 
 
3 
 
7.113 
 
 
5.870 
 
 
5.443 
 
.870 
 
 
.635 
 
 
.915 
 
5.146 
 
 
4.434 
 
 
3.372 
 
9.080 
 
 
7.306 
 
 
7.514 
 
 
 
Pairwise Comparisons 
 
Measure:   MEASURE_1 
 
 
(I) Meal (J) Meal 
 
Mean Difference 
 
(I-J) 
 
Std. Error Sig.
b
 
 
95% Confidence Interval for 
Difference
b
 
 
Lower Bound 
 
Upper Bound 
 
2 
1 
3 
 
 
1 
2 
3 
 
 
1 
3 
2 
 
1.243 
 
.640 
 
.084 
 
-.205 
 
2.691 
1.670
*
 
 
 
-1.243 
 
 
.427 
 
-1.670
*
 
 
.632 
 
 
.640 
 
 
1.035 
 
 
.632 
 
.027 
 
 
.084 
 
 
.690 
 
 
.027 
 
.239 
 
 
-2.691 
 
 
-1.914 
 
 
-3.101 
 
3.101 
 
 
.205 
 
 
2.768 
 
 
-.239 
 
-.427 
 
1.035 
 
.690 
 
-2.768 
 
1.914 
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Based on estimated marginal means 
 
 
*. The mean difference is significant at the .05 level. 
 
 
b. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
 
 
 
 
 
Multivariate Tests 
 
 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
.635 
 
 
.365 
 
 
1.742 
 
 
1.742 
6.968
a
 
 
6.968
a
 
 
6.968
a
 
 
6.968
a
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
8.000 
 
 
8.000 
 
 
8.000 
 
 
8.000 
 
.018 
 
 
.018 
 
 
.018 
 
 
.018 
 
.635 
 
 
.635 
 
 
.635 
 
 
.635 
 
 
 
Multivariate Tests 
 
 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
13.936 
 
 
13.936 
 
 
13.936 
 
 
13.936 
.788
a
 
 
.788
a
 
 
.788
a
 
 
.788
a
 
 
 
 
Each F tests the multivariate effect of Meal. These tests are based on the linearly independent pairwise 
comparisons among the estimated marginal means. 
 
a. Exact statistic 
 
 
b. Computed using alpha = .05 
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GLM FMD_25_4 FMD_50_4 FMD_75_4 
 
/WSFACTOR=Meal 3 Polynomial 
 
/METHOD=SSTYPE(3) 
 
/EMMEANS=TABLES(Meal) COMPARE ADJ(LSD) 
 
/PRINT=DESCRIPTIVE ETASQ OPOWER 
 
/CRITERIA=ALPHA(.05) 
 
/WSDESIGN=Meal. 
 
General Linear Model- one-way repeated measures ANOVA for FMD at 4 hrs 
 
[DataSet1] E:\Documents\Thesis (Lipid Load)\SPSS\FMD Data.sav 
 
 
Within-Subjects Factors 
 
 
Measure:   MEASURE_1 
 
 
Meal 
 
Dependent 
 
Variable 
 
1 
 
 
2 
 
 
3 
 
FMD_25_4 
 
 
FMD_50_4 
 
 
FMD_75_4 
 
 
 
Descriptive Statistics 
 
 
 
Mean 
 
Std. Deviation 
 
N 
 
FMD_25_4 
 
 
FMD_50_4 
 
 
FMD_75_4 
 
7.6030 
 
 
5.6560 
 
 
4.5730 
 
2.31800 
 
 
1.79071 
 
 
2.80037 
 
10 
 
 
10 
 
 
10 
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Multivariate Tests
a
 
 
 
Effect 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meal 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.549 4.866
b
 
 
2.000 
 
8.000 
 
.041 
 
.451 4.866
b
 
 
2.000 
 
8.000 
 
.041 
 
1.217 4.866
b
 
 
2.000 
 
8.000 
 
.041 
 
1.217 4.866
b
 
 
2.000 
 
8.000 
 
.041 
 
 
Multivariate Tests
a
 
 
 
Effect 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's Trace 
 
 
Wilks' Lambda 
Meal 
Hotelling's Trace 
 
 
Roy's Largest Root 
 
.549 9.733
b
 
 
.628 
 
.549 9.733
b
 
 
.628 
 
.549 9.733
b
 
 
.628 
 
.549 9.733
b
 
 
.628 
 
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meal 
b. Exact statistic 
c. Computed using alpha = .05 
148  
 
 
 
Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Mauchly's W 
 
Approx. Chi- 
Square 
 
df 
 
Sig. Epsilon
b
 
 
Greenhouse- 
Geisser 
 
Meal 
 
.758 
 
2.220 
 
2 
 
.330 
 
.805 
 
 
Mauchly's Test of Sphericity
a
 
 
Measure:   MEASURE_1 
 
 
Within Subjects Effect 
 
Epsilon 
 
Huynh-Feldt 
 
Lower-bound 
 
Meal 
 
.954 
 
.500 
 
 
 
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix.
a
 
 
a. Design: Intercept 
 
 
Within Subjects Design: Meal 
 
 
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are 
displayed in the Tests of Within-Subjects Effects table. 
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Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Meal 
Huynh-Feldt 
 
 
Lower-bound 
 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
Error(Meal) 
Huynh-Feldt 
 
 
Lower-bound 
 
47.149 
 
2 
 
23.574 
 
7.228 
 
.005 
 
47.149 
 
1.610 
 
29.287 
 
7.228 
 
.009 
 
47.149 
 
1.908 
 
24.713 
 
7.228 
 
.006 
 
47.149 
 
 
58.708 
 
1.000 
 
 
18 
 
47.149 
 
 
3.262 
 
7.228 
 
.025 
 
58.708 
 
14.489 
 
4.052   
 
58.708 
 
17.170 
 
3.419   
 
58.708 
 
9.000 
 
6.523   
 
 
 
Tests of Within-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Source 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
 
 
 
 
Meal 
 
 
 
 
 
 
 
Error(Meal) 
 
Sphericity Assumed 
Greenhouse-Geisser 
Huynh-Feldt 
Lower-bound 
 
 
Sphericity Assumed 
 
 
Greenhouse-Geisser 
 
.445 
 
14.456 
 
.888 
 
.445 
 
11.636 
 
.826 
 
.445 
 
13.790 
 
.875 
 
.445 
 
7.228 
 
.668 
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Huynh-Feldt 
 
 
Lower-bound 
   
   
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meal 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Linear 
Meal 
Quadratic 
 
 
Linear 
Error(Meal) 
Quadratic 
 
45.904 
 
1 
 
45.904 
 
9.493 
 
.013 
 
1.244 
 
 
43.521 
 
1 
 
 
9 
 
1.244 
 
 
4.836 
 
.737 
 
.413 
 
15.187 
 
9 
 
1.687   
 
 
 
Tests of Within-Subjects Contrasts 
 
Measure:   MEASURE_1 
 
 
Source Meal 
 
Partial Eta Squared 
 
Noncent. Parameter 
 
Observed Power 
 
Linear 
Meal 
Quadratic 
 
 
Linear 
Error(Meal) 
Quadratic 
 
.513 
 
9.493 
 
.783 
 
.076 
 
.737 
 
.120 
   
 
 
 
a. Computed using alpha = .05 
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Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Type III Sum of 
 
Squares 
 
df 
 
Mean Square 
 
F 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Intercept 
 
 
Error 
 
1059.934 
 
 
89.088 
 
1 
 
 
9 
 
1059.934 
 
 
9.899 
 
107.078 
 
.000 
 
.922 
 
 
 
Tests of Between-Subjects Effects 
 
Measure:   MEASURE_1 
 
 
Transformed Variable:   Average 
 
 
Source 
 
Noncent. Parameter 
 
Observed Power 
 
Intercept 
 
 
Error 
 
107.078 
 
1.000 
 
 
 
a. Computed using alpha = .05 
 
 
 
 
Estimated Marginal Means 
 
Meal 
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Estimates 
 
Measure:   MEASURE_1 
 
 
Meal 
 
Mean 
 
Std. Error 
 
95% Confidence Interval 
 
Lower Bound 
 
Upper Bound 
 
1 
 
 
2 
 
 
3 
 
7.603 
 
 
5.656 
 
 
4.573 
 
.733 
 
 
.566 
 
 
.886 
 
5.945 
 
 
4.375 
 
 
2.570 
 
9.261 
 
 
6.937 
 
 
6.576 
 
 
 
Pairwise Comparisons 
 
Measure:   MEASURE_1 
 
 
(I) Meal (J) Meal 
 
Mean Difference 
 
(I-J) 
 
Std. Error Sig.
b
 
 
95% Confidence Interval for 
Difference
b
 
 
Lower Bound 
 
Upper Bound 
 
2 
1 
3 
 
 
1 
2 
3 
 
 
1 
3 
2 
1.947
*
 
 
.663 
 
.017 
 
.446 
 
3.448 
3.030
*
 
 
-1.947
*
 
 
 
1.083 
 
-3.030
*
 
 
.983 
 
 
.663 
 
 
.741 
 
 
.983 
 
.013 
 
 
.017 
 
 
.178 
 
 
.013 
 
.805 
 
 
-3.448 
 
 
-.594 
 
 
-5.255 
 
5.255 
 
 
-.446 
 
 
2.760 
 
 
-.805 
 
-1.083 
 
.741 
 
.178 
 
-2.760 
 
.594 
 
 
 
Based on estimated marginal means 
 
 
*. The mean difference is significant at the .05 level. 
 
 
b. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
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Multivariate Tests 
 
 
 
Value 
 
F 
 
Hypothesis df 
 
Error df 
 
Sig. 
 
Partial Eta 
 
Squared 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
.549 
 
 
.451 
 
 
1.217 
 
 
1.217 
4.866
a
 
 
4.866
a
 
 
4.866
a
 
 
4.866
a
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
 
2.000 
 
8.000 
 
 
8.000 
 
 
8.000 
 
 
8.000 
 
.041 
 
 
.041 
 
 
.041 
 
 
.041 
 
.549 
 
 
.549 
 
 
.549 
 
 
.549 
 
 
 
Multivariate Tests 
 
 
 
Noncent. Parameter 
 
Observed Power 
 
Pillai's trace 
Wilks' lambda 
Hotelling's trace 
Roy's largest root 
 
9.733 
 
 
9.733 
 
 
9.733 
 
 
9.733 
.628
a
 
 
.628
a
 
 
.628
a
 
 
.628
a
 
 
 
 
Each F tests the multivariate effect of Meal. These tests are based on the linearly independent pairwise 
comparisons among the estimated marginal means. 
 
a. Exact statistic 
 
 
b. Computed using alpha = .05 
 
T-TEST PAIRS=FMD_25 FMD_25 FMD_50 WITH FMD_50 FMD_75 FMD_75 (PAIRED) 
 
/CRITERIA=CI(.9500) 
 
/MISSING=ANALYSIS. 
 
t-Test for FMD 
 
[DataSet1] E:\Documents\Thesis (Lipid Load)\SPSS\FMD Data.sav 
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Paired Samples Statistics 
 
 
 
Mean 
 
N 
 
Std. Deviation 
 
Std. Error Mean 
 
FMD_25 
Pair 1 
FMD_50 
 
 
FMD_25 
Pair 2 
FMD_75 
 
 
FMD_50 
Pair 3 
FMD_75 
 
7.3490 
 
30 
 
2.35165 
 
.42935 
 
6.3737 
 
 
7.3490 
 
 
5.6757 
 
 
6.3737 
 
30 
 
 
30 
 
 
30 
 
 
30 
 
2.17597 
 
 
2.35165 
 
 
2.89908 
 
 
2.17597 
 
.39728 
 
 
.42935 
 
 
.52930 
 
 
.39728 
 
5.6757 
 
30 
 
2.89908 
 
.52930 
 
 
 
Paired Samples Correlations 
 
 
 
N 
 
Correlation 
 
Sig. 
 
Pair 1 FMD_25 & FMD_50 
 
 
Pair 2 FMD_25 & FMD_75 
 
 
Pair 3 FMD_50 & FMD_75 
 
30 
 
 
30 
 
 
30 
 
.499 
 
 
.494 
 
 
.534 
 
.005 
 
 
.006 
 
 
.002 
 
 
 
Paired Samples Test 
 
 
 
Paired Differences 
 
Mean 
 
Std. Deviation 
 
Std. Error Mean 
 
95% Confidence Interval of the 
 
Difference 
 
Lower 
 
Upper 
 
Pair 1 FMD_25 - FMD_50 
 
 
Pair 2 FMD_25 - FMD_75 
 
.97533 
 
 
1.67333 
 
2.27161 
 
 
2.68333 
 
.41474 
 
 
.48991 
 
.12710 
 
 
.67136 
 
1.82357 
 
 
2.67531 
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Pair 3 FMD_50 - FMD_75 .69800 2.52995 .46190 -.24670 1.64270 
 
 
 
 
Paired Samples Test 
 
 
 
t 
 
df 
 
Sig. (2-tailed) 
 
Pair 1 FMD_25 - FMD_50 
 
 
Pair 2 FMD_25 - FMD_75 
 
 
Pair 3 FMD_50 - FMD_75 
 
2.352 
 
 
3.416 
 
 
1.511 
 
29 
 
 
29 
 
 
29 
 
.026 
 
 
.002 
 
 
.142 
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IRB Study #0907000527 
 
INDIANA UNIVERSITY BLOOMINGTON 
INFORMED CONSENT STATEMENT 
 
Lipemia, oxidative stress and endothelial function: a dose response. 
 
You are invited to participate in a research study of how much high-fat meals affect your artery 
health.  You were selected as a possible subject because you are a healthy adult between 18 
and 40 years of age. We ask that you read this form and ask any questions you may have 
before agreeing to be in the study. 
 
The study is being conducted by Janet P. Wallace, Ph.D., and Sylvanna Bielko, B.A., from the 
Clinical Exercise Physiology Laboratory, Department of Kinesiology, School of Health, Physical 
Education and Recreation, Indiana University, Bloomington. This study is not currently funded. 
 
 
 
STUDY PURPOSE 
 
The purpose of this study is to find the relationship between the fat content of a meal and its 
effects on artery health and oxidative stress. 
 
 
 
NUMBER OF PEOPLE TAKING PART IN THE STUDY: 
 
If you agree to participate, you will be one of twenty subjects who will be participating in this 
research. 
 
 
 
PROCEDURES FOR THE STUDY: 
 
If you agree to be in the study, you will be asked to participate in screening, laboratory testing, 
and three high-fat meals.  Each meal will have a different fat content; ranging from 25% to 75%. 
The following procedures will be done at each meal challenge. There will be three separate 
meal challenges over a 7-10 day period: 
 
1.  Screening 
 
a. Blood Draw at IU Health Center (20-30 min) 
 
Screening blood draw for cholesterol and triglycerides will be taken at the IU Health Center. 
 
Approximately 20-45 ml (4-8 ½ teaspoons) of venous blood will be drawn by a certified 
technician via   sterile techniques. 
 
2. Laboratory Testing (60-90 min) 
 
The laboratory testing will occur on a separate day before scheduling the three 
high-fat meals. 
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a.  Medical History – Health Habit Questionnaire 
You will be asked to complete a questionnaire on hospitalization, medications, family 
history and risk factors for coronary heart disease. 
b.  Basic Laboratory Testing 
c.   Body Mass Index (kg/m2) will be calculated using height and weight.  Both height 
and weight will be taken without shoes and wearing as few clothes as possible. 
d.  Waist circumference will be measured using an inelastic vinyl tape measure. The 
site for the waist will be the horizontal plane, a the level of the narrowest part of 
the torso, between the 10th rib and the iliac crest; while you are standing erect, 
with relaxed abdomen, arms by the side, and feet together.  Three measurements 
will be taken to the nearest 0.1 cm; the average of the three measurements will be 
used to calculate the waist circumference. 
e.  Nutrition/Diet:  A 3 month food frequency questionnaire will be analyzed for caloric 
intake (kcal/day); total fat & saturated fat, carbohydrate & protein; (g or mg or 
percent of total caloric intake), and dietary antioxidants (E & C; mg). 
 
 
 
If you do not qualify for the study based on your results from either the screening 
blood draw or the laboratory testing, you will have the opportunity to receive the 
results. If you do not want the results, they will be destroyed. You will not receive 
payment for completing the screening blood draw or laboratory testing; payment 
is only for completing the high-fat meals. 
 
 
 
3. High-Fat Meal Challenges 
 
a.  High- Fat Meal - You will eat a high-fat breakfast meal consisting of mixtures of 
Ensure and whipping cream or heavy whipping cream. The flavor of Ensure will 
be your choice (, Homemade Vanilla, Creamy Milk Chocolate, Strawberries & 
Cream, or Butter Pecan): 
 
The meals will be given in a randomized order, meaning you will not necessarily receive in 
1-2-3 order.  Each meal will be provided on a separate day, which could take up to 5 hours 
to complete. 
 
 Meal 1 Meal 2 Meal 3 
Product 16 oz Ensure 
8 oz Ensure Plus 
14 oz Ensure Plus 
2.7 oz Heavy Whipping 
Cream 
6 oz Ensure Plus 
6 oz Heavy Whipping Cream 
Calories 850 kcal 860 kcal 863 kcal 
Percent Fat 25% 51% 78% 
 
 
Water will be allowed as needed.  Consuming the meal may take between 5-20 minutes. 
 
b.  Pre- & Post-Meal Blood Draws - Three blood draws (to determine the amount of fat in the 
meal) will be measured 1) at baseline and  2) at 2:00 and 4:00 hours following the meal. 
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A 22-24 gauage venous (vein) catheter will be inserted and remain in your left arm by a 
trained clinical exercise physiologist for approximately seven hours. Following each blood 
draw, the catheter will be flushed (cleaned) with normal saline. The total amount of blood 
drawn for the three blood draws will be 105-140 ml (21-28 teaspoons). Inserting the catheter 
should take 5-10 minutes and each blood draw should take 1-2 minutes. 
 
c.   Brachial Artery Flow-Mediated Dilation (FMD) - For the Measurement of Arterial Health 
 
To participate in the high-fat meals you must: 
 
• Not exercise for at least 12 hrs before each study 
• Not have any caffeine at least 8 hrs before each study 
• Not have any Vitamin supplementation for at least 8 hrs before each study 
• Not have any tobacco products at least 8 hrs before each study 
• Be fasting for the past 12 hrs 
• If you are on any medications that dilate your arteries and/or cannot be tested within the 
preparation criteria listed above you will be excluded from the study 
 
 
 
How well your artery expands with changes in blood flow is used to characterize the 
health of your arteries. We will perform the FMD measurement on your right arm, before 
and at 2 hours and 4 hours after the high-fat meal. Three EKG-electrodes will be placed 
on your chest and you will lie on your back in a dark, climate-controlled room (22-24oC or 
72-75
o
F) with both arms extended out to your sides. After resting for 20 minutes, an 
ultrasound scan of your upper arm will be taken. This may require several scans to 
obtain a clear image. Once a clear image has been obtained, a blood pressure cuff will 
be placed around your forearm and inflated to 250 mmHg to stop blood flow to your 
lower arm for 5 minutes. The cuff will then be deflated and we will measure your blood 
flow velocity (the speed at which the blood is flowing through the artery) for 10 seconds 
and additional ultrasounds scans will be taken for additional 2 minutes. The health of 
your artery will be expressed as a percentages of artery expansion with the increased 
blood flow, compared to the resting diameter. 
 
 
 
RISKS OF TAKING PART IN THE STUDY: 
 
While participating in this study, the risks and discomforts are minimal: 
 
1.  The risk associated with a fasting blood draw may include fainting, soreness, bruising, 
and/or swelling at the venipuncture site (area where venous (vein) catheter was 
located). 
 
2.  Challenge Meal: The fat content of this meal is consistent with the fat content of the 
American diet.  Diarrhea and/or stomach cramps may occur if you are not used to eating 
a high fat diet (50% high-fat meals). The high-fat meal will be prepared in the Metabolic 
Kitchen of the Human Performance Laboratory.  You will be encouraged, but not 
obligated, to consume and or finish the meal. 
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3.  Flow-Mediated Dilation (FMD): The risks associated with the placement of EKG 
electrodes may include redness and/or itching at the electrode sites. The risks 
associated with forearm occlusion (stopping blood flow to the lower part of your arm) 
when measuring FMD may include redness of the skin, bruising, numbness, pain, 
tingling of the fingers and discomfort while the cuff is inflated. The risks associated with 
ultrasound measurements may include skin irritation and pressure around the 
transducer sites. The risks associated with the Ultrasound lubricant gel are skin 
irritation and possible break out of rash.  Should a rash occur, the gel will be wiped off, 
warm compresses will be applied and oral Benedryl will be provided if needed. 
 
4.  Repetitive Blood Draw via Angiocath:  The risks associated with the blood draw via 
venous catheter  h may include infection, irritation and bruising of the skin, pain, 
discomfort, collapsed vein, multiple puncture sites, and fainting. This risk is minimized 
by having the catheter inserted in a supine (laying down) or seated position. This risk, 
although rare, is minimized by using proper sterile technique (such as sterilizing using 
alcohol swabs).  There is a chance of phlebitis which can cause redness, swelling, 
moderate discomfort, and fever for up to a few days after the catheter is removed. If mild 
symptoms of phlebitis  (swelling (inflammation) of vein caused by a blood clot)develop, 
warm compresses, alternating Tylenol® and Advil® will be indicated until the symptoms 
are gone (usually 12-72 hours).  If serious symptoms of phlebitis develop (ie. fever or 
red streaks up the arm) you will be instructed to seek medical care immediately.  This 
risk is minimized by using proper sterile technique. 
As in any study, the risks of possible loss of confidentiality exist. 
BENEFITS OF TAKING PART IN THE STUDY: 
The benefits to participation that are reasonable to expect include information on how a high-fat meal 
 
affects your artery health. 
 
 
COMPENSATION FOR YOUR TIME: 
 
 
To compensate for the time involved in participating in the study, you will be paid $50/meal for each 5 
hour Challenge Meal session for a total of $150. If you are unable to complete all three Challenge Meals, 
you will be paid $8/hr for the time spent in the lab for the Challenge Meal session. The method of 
disbursement will be a voucher which asks your name, social security number, address, and ownership 
status. These data are sent to accounts payable and you will receive a check in the mail. 
 
ALTERNATIVES TO TAKING PART IN THE STUDY: 
 
 
The only alternative to taking part in this study is to choose not to participate. 
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CONFIDENTIALITY 
 
Efforts will be made to keep your personal information confidential. We cannot guarantee 
absolute confidentiality.  Your personal information may be disclosed if required by law.  Your 
identity will be held in confidence in reports in which the study may be published. To protect 
your identity, data about your will be associated with an identification number (rather than your 
name) and stored in a locked file cabinet in a locked room in the Clinical Exercise Physiology 
Laboratory. Electronic data will be maintained on a secure drive on the HPER server. You will 
not be identified in any report of manuscript.  Data will be kept in a database and not be 
discarded. If a subject requests the information to be shared with their primary physician, we 
will summarize the data and report it to the physician. 
 
Organizations that may inspect and/or copy your research records for quality assurance and 
data analysis include groups such as the study investigator and his/her research associates, the 
IU Institutional Review Board or its designees, the study sponsor, the AAU/Bell Updyke 
Research Committee, and (as allowed by law) state or federal agencies, specifically the Office 
for Human Research Protections (OHRP) who may need to access your research records. 
 
CONTACTS FOR QUESTIONS OR PROBLEMS 
 
For questions about the study or a research-related injury, contact the researchers 
 
Janet P. Wallace, Ph.D. 812 855-6384 
 
Sylvanna Bielko, B.A. 812 855-7556 (lab) 
 
For questions about your rights as a research participant or to discuss problems, complaints or 
concerns about a research study, or to obtain information, or offer input, contact the IU Human 
Subjects office at (317) 278-3458 (for Indianapolis) or (812) 856-4242 (for Bloomington) or (800) 
696-2949. 
 
 
USE OF SPECIMENS 
 
Blood samples taken in this study will be stored and may be used for different research analyses later. 
 
 
I give my permission for my blood samples to be used for different research analyses at a later time. 
 
 
I do not give permission for my blood samples to be used for different research analyses at a later 
time. 
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FUTURE RESEARCH 
 
 
I give my permission to be contacted at later date(s) about later studies in which I may be interested. 
 
 
I give my permission to be contacted at later date(s) about later studies in which I may be 
interested. 
 
I do not give my permission to be contacted at later date(s) about later studies in which I may 
be interested. 
 
 
VOLUNTARY NATURE OF STUDY 
 
Taking part in this study is voluntary.  You may choose not to take part or may leave the study 
at any time.  Leaving the study will not result in any penalty or loss of benefits to which you are 
entitled.  Your decision whether or not to participate in this study will not affect your current or 
future relations with the investigator(s). 
 
 
SUBJECT’S CONSENT 
 
In consideration of all of the above, I give my consent to participate in this research study. 
 
I will be given a copy of this informed consent document to keep for my records. I agree to take 
part in this study. 
 
Subject’s Printed Name:   
 
Subject’s Signature:  Date:   
 
(must be dated by the subject) 
 
 
 
 
 
Printed Name of Person Obtaining Consent:   
 
Signature of Person Obtaining Consent:  Date:   
 
 
 
Form date: July 14, 2011 
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(#09-07000527) 
e-mail 
 
Thank you for your interest in this study. 
 
 
 
The purpose of this study is to see how high-fat meals affect your arteries. 
 
 
 
To be eligible for this study you must be 18 to 40 years of age, and must not: 
 
• Be active (>90 min/week) 
• Be lactose intolerant 
• Have had a heart attack, lung disease, or diabetes 
• Have gallbladder disease 
• Take medications that dilate your arteries such as nitroglycerin, prostacyclin, or 
verapamil 
• Take medications that lower your cholesterol such as statins 
• Take any oral contraceptives (birth control pills) 
• Have elevated cholesterol (>240 mg/dL) and/or triglycerides (>200 mg/dL) 
 
 
The larger commitment to this study would be participation in three breakfast challenge meals; 
each one being a different high-fat content. The meals will be mixtures of Ensure and whipping 
cream. 
 
 
 
More specifically, each meal challenge testing session will take about five hours.  We will take 
baseline measurements, have the meal, then take measurements again at 2 and 4 hours after 
the meal. The measurements we will take include an ultrasound picture of your artery and 
blood, drawing and analyzing blood, and take weight and height measurements. You will also 
be asked to have a fasting (no food or liquid for 8 hours prior) blood draw taken at the IU Health 
Center to measure your cholesterol. 
 
 
 
Would you like to visit the lab to see the equipment and testing areas and to talk more about the 
study?  Please contact Sylvanna Bielko or Janet Wallace, Ph.D at (812) 855-7556.
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Lipemia, oxidative stress and endothelial function: a dose response. 
 
(#0907000527) 
 
 
 
 
Telephone  & Face to Face Script 
 
 
 
 
Hello, my name is   and I am one of the study coordinators of the high-fat 
meal study at Indiana University. 
 
 
 
Thank you for your interest in this study. 
 
 
 
 
The purpose of this study is to see how high-fat meals affect your arteries. 
 
To be eligible for this study you must be 18 to 40 years of age or older, and must not: 
 
 
 
 
• Be active (>90 min/week) 
• Be lactose intolerant 
• Have had a heart attack, lung disease, or diabetes 
• Have gallbladder disease 
• Take medications that dilate your arteries such as nitroglycerin, prostacyclin, or 
verapamil 
• Take medications that lower your cholesterol such as statins 
• Take any oral contraceptives (birth control pills) 
• Have elevated cholesterol (>240 mg/dL) and/or triglycerides (>200 mg/dL) 
 
 
Do you meet these criteria? 
 
If the answer is NO: 
 
I am sorry; we need to control for these variables. Thank you for your time.  If you know of 
anyone who might be interested, please give them our phone number. 
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If the answer is YES: 
 
The larger commitment to this study would be participation in three breakfast challenge meals; 
each one being a different high-fat content. The meals will be mixtures of Ensure and 
whipping cream. Are you lactose intolerant? 
 
 
 
Are you still interested in participating? 
 
 
 
If the answer is NO: 
 
Thank you very much for calling. If you know of anyone who might be interested, please give 
them our phone number. 
 
 
 
If the answer is YES: 
 
More specifically, each meal will take at least five hours.  We will take baseline measurement, 
have the meal, then take measurements at 2 and 4 hours after the meal. The measurements 
we will take include an ultrasound picture of your artery and bloods.  You will also be asked to 
have a fasting blood draw taken at the IU Health Center to measure your cholesterol. 
 
 
 
Are you still interested in participating? 
 
 
 
 
If the answer is NO: 
 
Thank you very much for calling. If you know of anyone who might be interested, please give 
them our phone number. 
 
 
 
If the answer is YES: 
 
To participate, you also need to: 
 
 
 
 
• Fast for 12 hours 
• Not exercise or perform strenuous physical activity at least 12 hours before each 
testing session. 
• Not have any caffeine at least 8 hours before each testing session. 
• Not take any vitamin supplements at least 8 hours before each testing session. 
• Not have tobacco products at least 8 hours before each testing session. 
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Will you be able to follow these instructions? 
 
 
 
 
If the answer is NO: 
 
I am sorry; we need people who will be able to do these things. Thank you for your time.  If you 
know of anyone who might be interested, please give them our phone number. 
 
 
 
If the answer is YES: 
 
We need to schedule an appointment to go over the informed consent during which I will be 
able to describe all the procedures of the study in detail. This first appointment will take 15-20 
minutes. 
 
 
 
[Scheduling part] 
 
 
 
 
Thank you very much for your time. I look forward to meeting you on that day. 
Have a great day! 
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Lipemia, oxidative stress and endothelial function: a dose response. 
 
(#0907000527) 
 
 
 
Student Recruiting Script 
 
 
 
 
Hello, my name is   and I am one of the study coordinators of the exercise 
and high-fat meal study at Indiana University. 
 
We have a study we are conducting in the Clinical Exercise Physiology Lab. We are looking for 
people who don’t exercise more than 90 minutes a week. 
 
The purpose of this study is to see how high-fat meals affect your arteries. 
 
You will first be asked to go to the IU Health Center for a fasting blood draw to measure your 
cholesterol and triglycerides. After that you will drink three different breakfast meals on three 
separate mornings. The meals will be mixtures of Ensure and whipping cream.  Each meal will 
be a different fat content; 25, 50 and 75% fat. We will measure your artery response with 
ultrasound before and at 2 and 4 hours after the meal.  You will be asked to stay in the lab for 
the whole morning.   You can study and use our computers during this time. We will also take 
blood samples at each time to measure the oxidative stress (harmful effects) of the meals. 
 
To be eligible for this study you must be 18 years of age or older, and must  not: 
 
• Be active (>90 min/week) 
• Have had a heart attack, lung disease, or diabetes 
• Have gallbladder disease 
• Take medications that dilate your arteries such as nitroglycerin, prostacyclin, or 
verapamil 
• Take medications that lower your cholesterol such as a statin 
• Take any oral contraceptives (birth control pills) 
• Have elevated cholesterol (>240 mg/dL) and/or triglycerides (>200 mg/dL) 
• Be lactose intolerant 
 
 
We will leave this flyer in the back of the class. It has our contact information on it.  Please 
consider this study.  Parking for the study, blood draws, and breakfasts are free. 
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Indiana University 
 
Clinical Exercise Physiology Lab 
 
 
 
Medical History/Health Habit Questionnaire 
 
 
 
Name_   Age   Birthdate   
(Please print) Day/Month/Year 
 
Home address  Zip   
 
Work address  Zip   
 
Home phone  Cell phone  e-mail   
 
1.  LIST HOSPITALIZATION HISTORY 
Age of Hospitalization Reason for Hospitalization Duration of Stay Comments 
    
    
    
    
 
2.  LIST CHILDHOOD DISEASES  
Disease Age 
 
 
 
 
 
3.  LIST ALL MEDICATIONS PRESENTLY TAKING 
Medication Purpose Dose How Often 
    
    
    
    
    
 
4.  FAMILY HISTORY OF HEART DISEASE/STROKE 
Indicate immediate family members (parents, siblings, aunts, uncles) who have diagnosed heart disease/stroke and/or who 
have died from heart disease /stroke 
 
Relationship Type of Disease Age at Diagnosis Age at Death 
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5.  HIGH BLOOD PRESSURE 
a)   Have you ever been told you have high blood pressure?   Yes   No 
b)    If so, when?    
c)    Was any treatment recommended?     Yes   _No 
d)    If so, what?    
e)   Are you still undergoing that treatment?   Yes   _No 
f) If no, when did you stop?    
g)   List any family members who have had/had high blood pressure 
 
Relationship Age at Diagnosis 
 
 
 
 
 
 
 
6. DIABETES 
a)   Have you ever been told you have diabetes?     Yes   No 
b)    If so, when?    
c)    What type of treatment was recommended? 
Diet   Exercise   
Medication   Name of medication   Dose   Insulin   
d)   Are you still undergoing treatment?   Yes   _No 
e)    If no, when did you stop?    
f) List an family members who have had/had diabetes: 
Relationship Type of Disease* Age at Diagnosis 
   
   
   
   
   
   
* Either Type I (previously known as juvenile diabetes) or Type II (previously known as adult onset diabetes) 
 
7.  CHEST DISCOMFORT 
a)   Have you ever experienced chest discomfort?   Yes   _No 
b)   If so, when?                                                                                                                                                        
a.    Describe the nature of the discomfort                                                                                           
b.    What were you doing at the time?                                                                                                 
c. When does it disappear?                                                                                                                  
d.    Was medical advice sought?                   _Yes                        No 
e.    What type of evaluation was performed?    
 
f. What was the result/conclusion of this evaluation?    
 
g. Are you on any medication for chest discomfort?   Yes   No 
h.    If so, what?    How often?    
i. How much?   
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8.  ARRYTHMIAS 
a)   Have you ever experienced skipped heart beats, rapid heart rates or other arrhythmias? 
  Yes   No 
b)   If so, when?                                                                                                                                                        
c)    What?                                                                                                                                                                 
d)    Was medical advice sought?                   _Yes                        No 
e)    What type of evaluation was performed?                                                                                                   
 
f) What was the result/conclusion of this evaluation?    
 
g)   Are you on any medication as a result of this evaluation?   Yes   _No 
h)    If so, what?   How often?    
i) How much?    
 
9. MUSCULAR/SKELETAL PROBLEMS 
a)   Do you have any muscle or skeletal problems?     Yes   No 
b)    What?    
c)    Does this limit your ability to exercise?   Yes   _No 
d)   Has medical advice been sought?   Yes   _No 
e)    What was the conclusion of this medical evaluation?    
 
f)    Have you ever had any muscle or skeletal problems in the past?                 _Yes                      _No 
g)   What?                                                                                                                                                                 
h)    Was medical advice sought?                   Yes                        No 
i)     What was the conclusion of this medical examination?                                                                             
 
 
 
10. PHYSICAL ACTIVITY 
a)   Are you presently engaging in any type of physical activity?   _Yes   No 
 
Type of 
Exercise 
How Long 
(min) 
How often 
(days/week) 
How Hard 
(Light-Moderate-Hard) 
When Did You 
Start 
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b)   Have you engaged in any type of physical activity in the past?   _Yes   _No 
 
 
Type of 
Exercise 
How 
Long 
(min) 
 
How often 
(days/week) 
How Hard 
(Light- 
Moderate-Hard) 
When 
Did You 
Start 
When 
Did You 
Start 
When 
Did You 
Quit 
 
 
 
Why 
        
        
        
        
 
c)    Occupation                                                                               Years at present work status                     
d)    If retired, what was your occupation?                                                                                                          
e)    Do you consider your day:              Sedentary?             _Moderately active?               Heavy work? 
f)     How many hours do you spend sitting each day?                                            
 
11.  How many hours do you sleep a night?    Soundness of sleep:   
 
12.  STRESS 
a)   Do you consider your day stressful?   Yes   No 
b)    What is the nature of your stress?    
 
c)    How do you handle your stress?    
 
 
 
13. Which meals do you eat? 
 
 Daily Occasionally Never 
Breakfast    
Early morning snack    
Lunch    
Afternoon snack    
Dinner    
Bedtime snack    
 
14. WEIGHT 
a)   Do you consider yourself overweight?   Yes   No 
b)    How long have you been overweight?    
c)    How many pounds would you like to lose?    
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15.  SMOKING HISTORY 
a)   Do you smoke?   _Yes   No 
b)    How much?    
c)    Have you ever smoked in the past?   Yes   No 
d)    What did you smoke?    
e)    How many years?    
f) How much?    
g)    When did you stop?    
h)    Why?    
 
16.  ALCOHOL CONSUMPTION 
a)   Do you drink alcohol?   Yes   _No 
b)   What kind?         
c)    How often?        
d)    Did you ever use alcohol in the past?   Yes   No 
e)    What?    
f) How much?    
g)    How many years?    
How often?     
When did you start?    
 
17.  List any known allergies:   
 
 
 
 
Any additional pertinent information   
 
 
 
 
 
 
 
Signature   Date   
 
 
 
OFFICE USE ONLY 
NOTES:   
 
 
 
 
 
 
 
 
 
 
 
Signature   Date   
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BLOOD DRAW INSTRUCTIONS 
 
The Clinical Exercise Physiology lab for the study entitled “Lipemia, oxidative stress, and 
endothelial function: a dose response” requires that all individuals scheduled for testing have 
their blood drawn.  In order to us to obtain the blood chemistry results prior to your scheduled 
testing date, the blood draw needs to be done before   ,   . 
 
Please go to the Indiana University Health Center at the corner of 10th Street and Jordan 
Avenue for this procedure. The hours are Monday & Thursday from 8 am to 5:30 pm and 
Tuesday, Wednesday, & Friday from 8 am to 4:30 pm. They will have your name and will be 
expecting you.  From the parking lot entrance, the blood lab is the last room on the right side of 
the hall (Room 208). The blood draw will take 10-15 minutes.  Because you need to fast before 
having your blood drawn, DO NOT EAT 12 HOURS BEFORE THE PROCEDURE.  Thank you. 
 
 
 
Date:    
 
Participant Name:    
 
Participant DOB:     
 
Participant ID:     
 
 
 
 
The above person needs to have a lipid panel.  Fax completed results to 855-8179. 
 
 
 
 
CEP Lab: This information needs to be emailed to Donna Dayton at  ddayton@indiana.edu. 
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Clinical Exercise Physiology Lab 
 
Appointment Reminder for the study 
 
Lipemia, oxidative stress, and endothelial 
dysfunction: a dose response 
 
 
 
Name:   
 
You will need to come into the lab for the three high-fat breakfast meals on three separate days. 
Your three meals testing will take place on: 
 
Meal 1:    at    
 
date time 
 
Meal 2:    at   
 
date time 
 
Meal 3:    at   
 
date time 
 
In order to participate in the high-fat meals you must: 
 
• Not exercise for at least 12 hrs before each meal 
• Not have any caffeine at least 8 hrs before each meal 
• Not have any Vitamin supplementation for at least 8 hrs before each meal 
• Not have any tobacco products at least 8 hrs before each meal 
• Be fasting for the past 12 hrs; drink plain water only 
• If you are on any medications that dilate your arteries and/or cannot be tested within the 
preparation criteria listed above you will be excluded from the study 
 
Please make sure to wear a short sleeve shirt for each of the meals. You need your arms to be 
accessible for both the FMD and blood draws. 
 
If you have any questions or concerns, please contact Sylvanna Bielko via email at 
sbielko@indiana.edu or call (812) 855-7556 (lab) or (260) 437-1379 (Sylvanna’s personal cell) 
 
Thanks and see you soon! 
